



**Cochrane  
Library**

Cochrane Database of Systematic Reviews

## Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis (Review)

Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA

Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA.  
Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.  
*Cochrane Database of Systematic Reviews* 2016, Issue 1. Art. No.: CD011281.  
DOI: [10.1002/14651858.CD011281.pub2](https://doi.org/10.1002/14651858.CD011281.pub2).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER .....	1
ABSTRACT .....	1
PLAIN LANGUAGE SUMMARY .....	2
SUMMARY OF FINDINGS .....	3
BACKGROUND .....	7
OBJECTIVES .....	8
METHODS .....	8
RESULTS .....	12
Figure 1. ....	13
Figure 2. ....	16
Figure 3. ....	17
DISCUSSION .....	19
AUTHORS' CONCLUSIONS .....	19
ACKNOWLEDGEMENTS .....	20
REFERENCES .....	21
CHARACTERISTICS OF STUDIES .....	24
DATA AND ANALYSES .....	36
Analysis 1.1. Comparison 1 Insulin lispro versus regular insulin, Outcome 1 Time to resolution of diabetic ketoacidosis. ....	36
Analysis 1.2. Comparison 1 Insulin lispro versus regular insulin, Outcome 2 All-cause mortality. ....	37
Analysis 1.3. Comparison 1 Insulin lispro versus regular insulin, Outcome 3 Hypoglycaemic episodes. ....	37
Analysis 1.4. Comparison 1 Insulin lispro versus regular insulin, Outcome 4 Length of hospital stay. ....	37
Analysis 2.1. Comparison 2 Insulin aspart versus regular insulin, Outcome 1 Time to resolution of diabetic ketoacidosis. ....	38
Analysis 2.2. Comparison 2 Insulin aspart versus regular insulin, Outcome 2 All-cause mortality. ....	38
Analysis 2.3. Comparison 2 Insulin aspart versus regular insulin, Outcome 3 Hypoglycaemic episodes. ....	38
Analysis 2.4. Comparison 2 Insulin aspart versus regular insulin, Outcome 4 Length of hospital stay. ....	39
ADDITIONAL TABLES .....	39
APPENDICES .....	42
CONTRIBUTIONS OF AUTHORS .....	62
DECLARATIONS OF INTEREST .....	62
SOURCES OF SUPPORT .....	62
NOTES .....	63
INDEX TERMS .....	63

## [Intervention Review]

# Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis

Carlos A Andrade-Castellanos<sup>1</sup>, Luis Enrique Colunga-Lozano<sup>2</sup>, Netzahualpilli Delgado-Figueroa<sup>3</sup>, Daniel A Gonzalez-Padilla<sup>4</sup>

<sup>1</sup>Department of Emergency Medicine, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, Mexico. <sup>2</sup>Department of Critical Care Medicine, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Mexico. <sup>3</sup>Department of Pediatrics, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico. <sup>4</sup>Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain

**Contact address:** Carlos A Andrade-Castellanos, Department of Emergency Medicine, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Salvador Quevedo y Zubieta No. 750, Guadalajara, Jalisco, 44340, Mexico. [caandrade@hcg.gob.mx](mailto:caandrade@hcg.gob.mx).

**Editorial group:** Cochrane Metabolic and Endocrine Disorders Group.

**Publication status and date:** New, published in Issue 1, 2016.

**Citation:** Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. *Cochrane Database of Systematic Reviews* 2016, Issue 1. Art. No.: CD011281. DOI: [10.1002/14651858.CD011281.pub2](https://doi.org/10.1002/14651858.CD011281.pub2).

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of uncontrolled diabetes that mainly occurs in individuals with autoimmune type 1 diabetes, but it is not uncommon in some people with type 2 diabetes. The treatment of DKA is traditionally accomplished by the administration of intravenous infusion of regular insulin that is initiated in the emergency department and continued in an intensive care unit or a high-dependency unit environment. It is unclear whether people with DKA should be treated with other treatment modalities such as subcutaneous rapid-acting insulin analogues.

### Objectives

To assess the effects of subcutaneous rapid-acting insulin analogues for the treatment of diabetic ketoacidosis.

### Search methods

We identified eligible trials by searching MEDLINE, PubMed, EMBASE, LILACS, CINAHL, and the Cochrane Library. We searched the trials registers WHO ICTRP Search Portal and ClinicalTrials.gov. The date of last search for all databases was 27 October 2015. We also examined reference lists of included randomised controlled trials (RCTs) and systematic reviews, and contacted trial authors.

### Selection criteria

We included trials if they were RCTs comparing subcutaneous rapid-acting insulin analogues versus standard intravenous infusion in participants with DKA of any age or sex with type 1 or type 2 diabetes, and in pregnant women.

### Data collection and analysis

Two review authors independently extracted data, assessed studies for risk of bias, and evaluated overall study quality utilising the GRADE instrument. We assessed the statistical heterogeneity of included studies by visually inspecting forest plots and quantifying the diversity using the  $I^2$  statistic. We synthesised data using random-effects model meta-analysis or descriptive analysis, as appropriate.

### Main results

Five trials randomised 201 participants (110 participants to subcutaneous rapid-acting insulin analogues and 91 to intravenous regular insulin). The criteria for DKA were consistent with the American Diabetes Association criteria for mild or moderate DKA. The underlying cause of DKA was mostly poor compliance with diabetes therapy. Most trials did not report on type of diabetes. Younger diabetic participants and children were underrepresented in our included trials (one trial only). Four trials evaluated the effects of the rapid-acting insulin analogue lispro, and one the effects of the rapid-acting insulin analogue aspart. The mean follow-up period as measured by mean

**Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis (Review)**

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

hospital stay ranged between two and seven days. Overall, risk of bias of the evaluated trials was unclear in many domains and high for performance bias for the outcome measure time to resolution of DKA.

No deaths were reported in the included trials (186 participants; 3 trials; moderate- (insulin lispro) to low-quality evidence (insulin aspart)). There was very low-quality evidence to evaluate the effects of subcutaneous insulin lispro versus intravenous regular insulin on the time to resolution of DKA: mean difference (MD) 0.2 h (95% CI -1.7 to 2.1);  $P = 0.81$ ; 90 participants; 2 trials. In one trial involving children with DKA, the time to reach a glucose level of 250 mg/dL was similar between insulin lispro and intravenous regular insulin. There was very low-quality evidence to evaluate the effects of subcutaneous insulin aspart versus intravenous regular insulin on the time to resolution of DKA: MD -1 h (95% CI -3.2 to 1.2);  $P = 0.36$ ; 30 participants; 1 trial. There was low-quality evidence to evaluate the effects of subcutaneous rapid-acting insulin analogues versus intravenous regular insulin on hypoglycaemic episodes: 6 of 80 insulin lispro-treated participants compared with 9 of 76 regular insulin-treated participants reported hypoglycaemic events; risk ratio (RR) 0.59 (95% CI 0.23 to 1.52);  $P = 0.28$ ; 156 participants; 4 trials. For insulin aspart compared with regular insulin, RR for hypoglycaemic episodes was 1.00 (95% CI 0.07 to 14.55);  $P = 1.0$ ; 30 participants; 1 trial; low-quality evidence. Socioeconomic effects as measured by length of mean hospital stay for insulin lispro compared with regular insulin showed a MD of -0.4 days (95% CI -1 to 0.2);  $P = 0.22$ ; 90 participants; 2 trials; low-quality evidence and for insulin aspart compared with regular insulin 1.1 days (95% CI -3.3 to 1.1);  $P = 0.32$ ; low-quality evidence. Data on morbidity were limited, but no specific events were reported for the comparison of insulin lispro with regular insulin. No trial reported on adverse events other than hypoglycaemic episodes, and no trial investigated patient satisfaction.

### Authors' conclusions

Our review, which provided mainly data on adults, suggests on the basis of mostly low- to very low-quality evidence that there are neither advantages nor disadvantages when comparing the effects of subcutaneous rapid-acting insulin analogues versus intravenous regular insulin for treating mild or moderate DKA.

## PLAIN LANGUAGE SUMMARY

### Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis

#### Review question

What are the effects of subcutaneous rapid-acting insulin analogues compared with standard intravenous infusion of regular insulin for the treatment of diabetic ketoacidosis?

#### Background

Rapid-acting insulin analogues (artificial insulin such as insulin lispro, insulin aspart, or insulin glulisine) act more quickly than regular human insulin. In people with a specific type of life-threatening diabetic coma due to uncontrolled diabetes, called diabetic ketoacidosis, prompt administration of intravenous regular insulin is standard therapy. The rapid-acting insulin analogues, if injected subcutaneously, act faster than subcutaneously administered regular insulin. The need for a continuous intravenous infusion, an intervention that usually requires admission to an intensive care unit, can thereby be avoided. This means that subcutaneously given insulin analogues for diabetic ketoacidosis might be applied in the emergency department and a general medicine ward.

#### Study characteristics

We found five randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with a total of 201 participants. Most trials did not report on type of diabetes. Younger diabetic participants and children were underrepresented in our included trials (one trial only). Participants in four trials received treatment with insulin lispro, and one trial with 45 participants investigated insulin aspart. The average follow-up as measured by mean hospital stay ranged between two and seven days. The study authors termed the diabetic ketoacidosis being treated with insulin analogues or regular insulin as mild or moderate. This evidence is up to date as of October 2015.

#### Key results

Our results are most relevant for adults with mild or moderate diabetic ketoacidosis due to undertreatment of diabetes. No deaths occurred. Time to resolution of diabetic ketoacidosis from the start of therapy did not differ substantially between the two insulin treatment schemes (approximately 11 hours). Hypoglycaemic (low blood sugar) episodes were comparable: 118 per 1000 participants for intravenous insulin compared with 70 per 1000 participants for subcutaneous insulin lispro (no statistically significant difference). The mean length of hospital stay also showed no marked differences. No trial reported on side effects other than hypoglycaemic episodes or investigated patient satisfaction. No serious events associated with diabetic ketoacidosis were seen during insulin lispro treatment.

#### Quality of the evidence

Our results were limited by mostly low- to very low-quality evidence, mainly because the number of included trials and participants was low. Further research is very likely to have an important impact on our findings.

## SUMMARY OF FINDINGS

### Summary of findings for the main comparison. Subcutaneous insulin lispro versus intravenous regular insulin for diabetic ketoacidosis

#### Subcutaneous insulin lispro versus intravenous regular insulin for diabetic ketoacidosis

**Patient:** participants with diabetic ketoacidosis

**Settings:** emergency department and critical care unit

**Intervention:** subcutaneous insulin lispro versus intravenous regular insulin

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Intravenous regular insulin	Subcutaneous insulin lispro				
<b>All-cause mortality (N)</b>  Mean hospital stay: 2-7 days	See comment	See comment	Not estimable	156 (4)	⊕⊕⊕⊕ <b>moderate<sup>a</sup></b>	No deaths reported
<b>Hypoglycaemic episodes (N)</b>  Mean hospital stay: 2-7 days	<b>118 per 1000</b>	<b>70 per 1000</b> (27 to 180)	<b>RR 0.59</b> (0.23 to 1.52)	156 (4)	⊕⊕⊕⊕ <b>low<sup>b</sup></b>	Comparable risk ratios for adults (4 trials) and children (1 trial)
<b>Morbidity (N)</b>  Mean hospital stay: 2-7 days	See comment	See comment	Not estimable	96 (2)	See comment	No cases of cerebral oedema, venous thrombosis, adult respiratory distress syndrome, hyperchloraemic acidosis
<b>Adverse events other than hypoglycaemic episodes</b>	See comment	See comment	Not estimable	See comment	See comment	Not investigated
<b>Time to resolution of diabetic ketoacidosis (h)</b>  Mean hospital stay: 2-4 days	The mean time to resolution of diabetic ketoacidosis across the intravenous regular insulin groups was 11 h	The mean time to resolution of diabetic ketoacidosis in the subcutaneous insulin lispro groups was <b>0.2 h higher</b> (1.7 h lower to 2.1 h higher)	-	90 (2)	⊕⊕⊕⊕ <b>very low<sup>c</sup></b>	Metabolic acidosis and ketosis took longer to resolve in the subcutaneous insulin lispro group in 1 trial (60 children); no exact data published

Patient satisfaction	See comment	See comment	Not estimable	See comment	See comment	Not investigated
<b>Socioeconomic effects: length of hospital stay (days)</b>  Mean hospital stay: 4-7 days	The mean length of hospital stay in the intravenous regular insulin groups ranged between 4 and 6.6 days	The mean length of hospital stay in the subcutaneous insulin lispro groups was <b>0.4 days shorter</b> (1 day shorter to 0.2 days longer)	-	90 (2)	⊕⊕⊕⊕ <b>low<sup>d</sup></b>	US setting: treatment of diabetic ketoacidosis in a non-intensive care setting (step-down unit or general medicine ward) was associated with a 39% lower hospitalisation charge than was treatment with intravenous regular insulin in the intensive care unit (USD 8801 (SD USD 5549) vs USD 14,429 (SD USD 5243); the average hospitalisation charges per day were USD 3981 (SD USD 1067) for participants treated in an intensive care unit compared with USD 2682 (SD USD 636) for those treated in a non-intensive care setting

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; h: hours; RR: risk ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

\*Assumed risk was derived from the event rates in the comparator groups.

<sup>a</sup>Downgraded by one level because of imprecision (see [Appendix 12](#)).

<sup>b</sup>Downgraded by two levels because of risk of performance bias and serious imprecision (see [Appendix 12](#)).

<sup>c</sup>Downgraded by three levels because of risk of performance bias, serious risk of inconsistency, and serious risk of imprecision (see [Appendix 12](#)).

<sup>d</sup>Downgraded by two levels because of serious risk of imprecision (see [Appendix 12](#)).

## Summary of findings 2. Subcutaneous insulin aspart versus intravenous regular insulin for diabetic ketoacidosis

### Subcutaneous insulin aspart versus intravenous regular insulin for diabetic ketoacidosis

**Patient:** participants with diabetic ketoacidosis

**Settings:** general medicine ward and intensive care unit

**Intervention:** subcutaneous insulin aspart versus intravenous regular insulin

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				



	Intravenous regular insulin	Subcutaneous insulin aspart	(studies)			
<b>All-cause mortality (N)</b> Mean hospital stay: 3-5 days	See comment	See comment	Not estimable	45 (1)	⊕⊕⊕⊕ <b>low<sup>a</sup></b>	No deaths reported
<b>Hypoglycaemic episodes (N)</b> Mean hospital stay: 3-5 days	<b>67 per 1000</b>	<b>67 per 1000</b> (5 to 970)	<b>RR 1.00</b> (0.07 to 14.55)	30 (1)	⊕⊕⊕⊕ <b>low<sup>b</sup></b>	-
<b>Morbidity</b>	See comment	See comment	Not estimable	See comment	See comment	Not investigated
<b>Adverse events other than hypoglycaemic episodes</b>	See comment	See comment	Not estimable	See comment	See comment	Not investigated
<b>Time to resolution of diabetic ketoacidosis (h)</b> Mean hospital stay: 3-5 days	The mean time to resolution of diabetic ketoacidosis across the intravenous regular insulin groups was 11 h	The mean time to resolution of diabetic ketoacidosis in the subcutaneous insulin aspart group was <b>1 h lower</b> (3.2 h lower to 1.2 h higher)	-	30 (1)	⊕⊕⊕⊕ <b>very low<sup>c</sup></b>	-
<b>Patient satisfaction</b>	See comment	See comment	Not estimable	See comment	See comment	Not investigated
<b>Socioeconomic effects: length of hospital stay (days)</b> Mean hospital stay: 3-5 days	The mean length of hospital stay in the intravenous regular insulin group was 4.5 days	The mean length of hospital stay in the subcutaneous insulin aspart group was <b>1.1 days shorter</b> (3.3 days shorter to 1.1 days longer)	-	30 (1)	⊕⊕⊕⊕ <b>low<sup>d</sup></b>	-

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **h:** hours; **RR:** risk ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

\*Assumed risk was derived from the event rates in the comparator groups

<sup>a</sup>Downgraded by two levels because of serious imprecision (see [Appendix 12](#))

- <sup>b</sup>Downgraded by two levels because of risk of performance bias and imprecision (see [Appendix 12](#))
- <sup>c</sup>Downgraded by three levels because of risk of performance bias and serious risk of imprecision (see [Appendix 12](#))
- <sup>d</sup>Downgraded by two levels because of serious risk of imprecision (see [Appendix 12](#))



## BACKGROUND

### Description of the condition

Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. A consequence of this is chronic hyperglycaemia (that is elevated levels of plasma glucose) with disturbances of carbohydrate, fat, and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy, and neuropathy. The risk of cardiovascular disease is increased. Individuals with diabetes may be admitted to the hospital as a result of diabetic emergencies such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS). DKA is an acute, major, life-threatening complication of diabetes that occurs mainly in individuals with autoimmune type 1 diabetes, but it is not uncommon in some people with type 2 diabetes (Kitabchi 2009). DKA and HHS represent the most extreme consequences of uncontrolled diabetes mellitus.

In the USA, the incidence rate for DKA ranges from 4.6 to 8 episodes per 1000 people with diabetes of all ages, and 13.4 episodes per 1000 people with diabetes who are younger than 30 years old (Faich 1983; Johnson 1980). The incidence rate in the USA is comparable to the rates in Europe, with estimates of 13.6 per 1000 people with type 1 diabetes in the UK (Dave 2004). The mortality rate of DKA currently ranges from 0% to 19%, a rate that has shown a little decline in recent years (Basu 1993; Warner 1998). Mortality rates increase substantially with age and in the presence of concomitant life-threatening illnesses such as co-existent kidney disease and infections (Malone 1992). Hyperglycaemic crises are also economically burdensome, as DKA is responsible for more than 500,000 hospital days per year at an estimated annual direct medical expense and indirect cost of USD 2.4 billion (Kim 2007).

The basic mechanism for the development of DKA is a reduction in the effective insulin concentration and increased counter-regulatory (catabolic or stress) hormones like glucagon, catecholamine, cortisol, and growth hormone. The hyperglycaemia of DKA results from increased hepatic glucose production (gluconeogenesis and glycogenolysis) and impaired peripheral glucose utilisation. Ketone bodies result from a marked increase in the free fatty acid release from adipocytes, with a resulting shift toward ketone body synthesis in the liver. This hormonal imbalance leads to the biochemical triad of DKA: hyperglycaemia, ketonaemia, and acidaemia (Kitabchi 2001). People with DKA are invariably volume depleted because insulin deficiency in DKA leads to hyperglycaemic osmotic diuresis and progressive volume depletion. Glycosuria is also accompanied by large urinary losses of potassium and phosphorus. The above processes can have several consequences, including tissue hypoxia, hyperviscosity, arrhythmia, and decreased blood flow to target organs like the brain.

Successful treatment of DKA requires correction of hyperglycaemia, skillful fluid and electrolyte adjustments, identification of comorbid precipitating events, and above all frequent and close monitoring of the patient (Kitabchi 2009). The treatment of diabetic ketoacidosis is traditionally accomplished by the administration of intravenous infusion of regular insulin, which is initiated in the emergency department and continued in an intensive care unit (ICU) or a high-dependency unit environment, as endorsed by the American Diabetes Association and the Joint British Diabetes

Societies guideline for the management of DKA (Kitabchi 2009; Savage 2011).

### Description of the intervention

The first priority in the treatment of DKA is to restore intravascular volume to normalise tissue perfusion and aid in the delivery of insulin to target organs. Insulin administration is essential in the treatment and is initiated immediately, unless there is evidence of severe hypovolaemia or hypokalaemia. Insulin therapy lowers the serum glucose concentration primarily by decreasing hepatic glucose production rather than enhancing peripheral utilisation (Luzi 1988), diminishes ketone production (by reducing both lipolysis and glucagon secretion), and may augment ketone clearance. Insulin administration seeks to restore normal glucose uptake by cells; however, excessive insulin administration must be avoided to prevent hypoglycaemia and hypokalaemia.

The route of administration of insulin in the management of DKA has been debated since the early 1970s. Alberti 1973 reported the results of low-dose intramuscular insulin in the management of people with DKA. They found that an initial average bolus dose of 16 units followed by 5 to 10 units of intramuscular regular insulin per hour was effective in correcting hyperglycaemia and acidaemia. Later in the 1970s, Fisher and colleagues reported a greater decline in blood glucose and ketone body levels in the first two hours of therapy with intravenous insulin as compared to intramuscular or subcutaneous insulin (Fisher 1977). Furthermore, the dehydration and shock state of people with DKA leads to erratic and unpredictable absorption of intramuscular and subcutaneous insulin (Fisher 1977). Based on this finding, it is now generally accepted that continuous intravenous infusion is the most effective route of insulin administration (Savage 2011).

Randomised controlled trials in people with DKA have shown insulin therapy to be effective regardless of the administration route. Treatment with subcutaneous rapid-acting insulin analogues administered every one to two hours has been shown to be an effective alternative to the use of intravenous regular insulin in the treatment of uncomplicated DKA (Umpierrez 2004a; Umpierrez 2004b). In one of these trials, the authors found that the effects in people treated with subcutaneous insulin lispro were comparable with those treated with intravenous regular insulin. The authors observed similar rates of death, length of hospital stay, and amount of insulin used until resolution of DKA between treatment groups. Treatment of DKA in the ICU was associated with 39% higher hospitalisation charges than was treatment with subcutaneous lispro in a non-intensive care setting (Umpierrez 2004b).

### Adverse effects of the intervention

Hypoglycaemia is an inherent adverse effect of insulin treatment. Additionally, insulin therapy is associated with injection site reactions, generalised sensitivity reactions, and electrolyte imbalances such as hypokalaemia. Concern has been raised regarding potential mitogenic effects of insulin analogues, but evidence is controversial (Hemkens 2009; Kurtzhals 2000). Insulin lispro and insulin aspart, like human insulin, are rated category B for pregnancy use, which means that well-controlled trials in pregnant women are lacking, while insulin glulisine is category C, because only animal reproduction studies have been performed with it (Home 2012).

## How the intervention might work

In the last decade, considerable attention has been devoted to the development of insulin analogues with pharmacokinetic profiles that differ from existing insulin preparations. Compared to regular human insulin, proline at position 28 and lysine at position 29 of the B-region were interchanged in the short-acting insulin analogue lispro. In the short-acting insulin analogue aspart, proline at position 28 of the B-region was replaced by aspartic acid, and in the short-acting insulin analogue glulisine, the amino acid asparagine was replaced by lysine at position three and lysine with glutamic acid at position 29 of the B-chain (Siebenhofer 2006). Insulin lispro, insulin aspart, and insulin glulisine have very similar pharmacokinetic profiles. These analogues are present either in a monomeric form or a very weakly bound hexameric form. Following subcutaneous injection, they are rapidly absorbed in less than 30 minutes, with a short peak time of insulin concentration of 1 hour and a shorter duration of action of 3 to 4 hours when compared with regular human insulin (Roach 2008).

Data on rapid-acting insulin analogues in clinical trials (not in DKA) suggest lower postprandial glucose variations when compared with meal-time human insulin in adults and children, and in type 1 and type 2 diabetes (Home 2000; Mathiesen 2007; Rayman 2007). The decreased incidence of major hypoglycaemia requiring third-party assistance, in particular major nocturnal hypoglycaemia, is the expected consequence of the shorter subcutaneous availability time of rapid-acting insulin analogues. In people with type 1 diabetes, the median incidence of severe hypoglycaemia for rapid-acting analogues is 21.8 episodes per 100 person-years compared with 46.1 episodes for human insulin (Siebenhofer 2006). In people with type 2 diabetes, the median incidence is 0.3 episodes per 100 person-years for analogues compared with a mean of 1.4 episodes per 100 person-years for human insulin (Siebenhofer 2006).

The pharmacokinetic profile of rapid-acting analogues following subcutaneous injection suggests that they might be a feasible alternative in the case of DKA, that is faster rise in plasma concentration, higher peak concentration, and shorter subcutaneous residence time than unmodified human insulin (Howey 1995).

## Why it is important to do this review

As an alternative to an intravenous infusion of regular insulin, people with mild to moderate DKA can be treated with subcutaneous rapid-acting insulin analogues, offering an opportunity to avoid costly admissions (Kitabchi 2009; Nyenwe 2011; Umpierrez 2004a; Umpierrez 2004b). Delivery of care without constant patient monitoring (for example outside ICU settings) will undoubtedly reduce cost. Also, stable patients could be treated in a step-down unit close to their relatives.

Two systematic reviews comparing rapid-acting insulin analogues with intravenous infusion of regular insulin in the treatment of mild to moderate DKA have been published (Mazer 2009; Vincent 2013). Both reviews provide an overview of the studies located, however there are some limitations. Firstly, the comprehensiveness of systematic literature searches was suboptimal. The literature search in Vincent 2013 was restricted exclusively to the PubMed database. Secondly, assessments of risk of bias of studies were not specified (Mazer 2009; Vincent 2013).

Given the limitations of previous systematic reviews, we plan to use specific methodology and criteria outlined by Cochrane in our aim to present a comprehensive systematic review to assess the efficacy and safety of subcutaneous rapid-acting insulin analogues in the treatment of DKA in adults and children.

## OBJECTIVES

To assess the effects of subcutaneous rapid-acting insulin analogues for the treatment of diabetic ketoacidosis.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised controlled trials (RCTs).

#### Types of participants

We included trials evaluating participants with diabetic ketoacidosis (DKA) of any age or sex with type 1 or type 2 diabetes, and pregnant women (including gestational diabetes).

#### Diagnostic criteria for diabetes mellitus

In order to be consistent with changes in classification and diagnostic criteria of diabetes mellitus over the years, we used the diagnostic criteria valid at the time of the trial commencing (for example ADA 1999; ADA 2008; WHO 1998). We used the study authors' definition of diabetes mellitus if necessary. We planned to subject diagnostic criteria to a sensitivity analysis.

#### Diagnostic criteria for diabetic ketoacidosis

We used the American Diabetes Association criteria for DKA (ADA 2004), which are as follows.

- Mild DKA: plasma glucose > 250 mg/dL, arterial pH 7.25 to 7.30, serum bicarbonate 15 to 18 mEq/L, urine and serum ketones positive, anion gap > 10, alteration in sensoria or mental obtundation as alert.
- Moderate DKA: plasma glucose > 250 mg/dL, arterial pH 7.00 to 7.24, serum bicarbonate 10 to < 15 mEq/L, urine and serum ketones positive, anion gap > 12, alteration in sensoria or mental obtundation as alert/drowsy.
- Severe DKA: plasma glucose > 250 mg/dL, arterial pH < 7.00, serum bicarbonate < 10 mEq/L, urine and serum ketones positive, anion gap > 12, alteration in sensoria or mental obtundation as stupor/coma.

#### Types of interventions

We planned to investigate the effects of subcutaneous rapid-acting insulin analogues versus standard intravenous infusion of regular insulin. We expected insulin regimens (use of intravenous bolus, dose, and frequency) to vary depending on the study, therefore we accepted all insulin regimens.

#### Intervention

- Subcutaneous rapid-acting insulin analogues (insulin lispro, insulin aspart, or insulin glulisine).

## Comparator

- Intravenous infusion of regular insulin.

Concomitant interventions had to be the same in the intervention and comparator groups to establish fair comparisons.

## Types of outcome measures

### Primary outcomes

- Time to resolution of DKA.
- All-cause mortality.
- Hypoglycaemic episodes.

### Secondary outcomes

- Morbidity.
- Adverse events other than hypoglycaemia.
- Patient satisfaction.
- Glycosylated haemoglobin A1c (HbA1c).
- Socioeconomic effects.

### Method and timing of outcome measurement

- Time to resolution of DKA: defined as time to reach blood glucose levels < 200 mg/dL and two of the following criteria: a serum bicarbonate level  $\geq 15$  mEq/L, a venous pH > 7.3, and a calculated anion gap  $\leq 12$  mEq/L (Kitabchi 2009).
- All-cause mortality: defined as the total number of deaths from any cause and measured as in-hospital mortality and 30-day all-cause mortality.
- Hypoglycaemic episodes: defined as a symptomatic or asymptomatic event with plasma glucose  $\leq 70$  mg/dL (3.9 mmol/L) or according to authors' definition.
- Morbidity: such as cerebral oedema defined by diagnostic criteria, including abnormal motor or verbal responses to pain, decorticate posture, and abnormal neurogenic respiratory patterns (major, but not diagnostic criteria include altered mentation, sustained heart rate decelerations, and age-inappropriate incontinence; minor criteria include vomiting, headache, lethargy, diastolic blood pressure > 90 mm Hg, and age < 5 years (Muir 2004)).
- Adverse events other than hypoglycaemia: such as hypokalaemia defined as a serum potassium concentration < 3.5 mEq/L, and injection site reactions.
- Patient satisfaction: evaluated with a validated instrument such as the Insulin Treatment Satisfaction Questionnaire (Anderson 2004).
- HbA1c: measured at hospital admission (baseline) and at three months postdischarge.
- Socioeconomic effects: such as length of hospital stay, calculated by subtracting day of admission from day of discharge, and costs, measured as data on hospital charges.

### 'Summary of findings' table

We present a 'Summary of findings' table reporting the following outcomes listed according to priority.

1. All-cause mortality.
2. Hypoglycaemic episodes.
3. Morbidity.

4. Adverse events other than hypoglycaemic episodes.
5. Time to resolution of DKA.
6. Patient satisfaction.
7. Socioeconomic effects.

## Search methods for identification of studies

### Electronic searches

We searched the following sources from inception of each database to the specified date and placed no restrictions on the language of publication.

- Cochrane Library (27 October 2015)
  - \* Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 9, September 2015)
  - \* Database of Abstracts of Reviews of Effects (DARE) (Issue 2, April 2015)
  - \* Health Technology Assessment (HTA) Database (Issue 3, July 2015)
- Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) (1946 to 27 October 2015)
- PubMed (segments not available on Ovid) (27 October 2015)
- EMBASE (1974 to 26 October 2015)
- LILACS (23 October 2015)
- CINAHL (27 October 2015)
- ClinicalTrials.gov (<http://www.clinicaltrials.gov>, 27 October 2015)
- WHO ICTRP Search Portal (<http://apps.who.int/trialsearch/>) (27 October 2015):
  - \* Australian New Zealand Clinical Trials Registry (19 October 2015)
  - \* Chinese Clinical Trial Registry (19 October 2015)
  - \* ClinicalTrials.gov (19 October 2015)
  - \* EU Clinical Trials Register (EU-CTR) (19 October 2015)
  - \* ISRCTN (19 October 2015)
  - \* The Netherlands National Trial Register (19 October 2015)
  - \* Brazilian Clinical Trials Registry (ReBec) (13 October 2015)
  - \* Clinical Trials Registry - India (13 October 2015)
  - \* Clinical Research Information Service - Republic of Korea (13 October 2015)
  - \* Cuban Public Registry of Clinical Trials (13 October 2015)
  - \* German Clinical Trials Register (13 October 2015)
  - \* Iranian Registry of Clinical Trials (4 August 2015)
  - \* Japan Primary Registries Network (19 October 2015)
  - \* Pan African Clinical Trial Registry (13 October 2015)
  - \* Sri Lanka Clinical Trials Registry (13 October 2015)
  - \* Thai Clinical Trials Register (TCTR) (13 October 2015)

We continuously applied a MEDLINE (via Ovid) email alert service to identify newly published studies using the same search strategy as described for MEDLINE (for details on search strategies see Appendix 1). After supplying the final review draft for editorial approval, the Cochrane Metabolic and Endocrine Disorders Group performed a complete updated search on all databases available at the editorial office and sent the results to the review authors. Should we have identified new trials for inclusion, we evaluated

these, incorporated the findings into our review, and resubmitted another review draft (Beller 2013).

We planned to evaluate any newly identified studies for inclusion, incorporate the findings into our review, and resubmit another review draft (Beller 2013).

If we detected additional relevant key words during any of the electronic or other searches, we would have modified the electronic search strategies to incorporate these terms and document the changes to the search strategy.

### Searching other resources

We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, (systematic) reviews, meta-analyses, and health technology assessment reports.

## Data collection and analysis

### Selection of studies

Two review authors (CAC, LCL) independently reviewed the abstract, title, or both, of every record retrieved in order to determine which trials should be assessed further. We investigated all potentially relevant articles as full text. We resolved any discrepancies through consensus or recourse to a third review author (NDF). If resolution of a disagreement was not possible, we planned to add the article to those 'awaiting assessment', and we would have contacted study authors for clarification. We have presented an adapted Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing the process of trial selection (Liberati 2009).

### Data extraction and management

For trials that fulfilled our inclusion criteria, two review authors (CAC, LCL) independently abstracted relevant population and intervention characteristics using standard data extraction templates (for details see [Characteristics of included studies](#); [Table 1](#); [Appendix 2](#); [Appendix 3](#); [Appendix 4](#); [Appendix 5](#); [Appendix 6](#); [Appendix 7](#); [Appendix 8](#); [Appendix 9](#); [Appendix 10](#); [Appendix 11](#); [Appendix 12](#)), with any disagreements to be resolved by discussion, or, if required, by a third review author (NDF).

We have provided information including trial identifier about potentially relevant ongoing trials in [Characteristics of ongoing studies](#) and in [Appendix 5](#) ('Matrix of study endpoints (publications and trial documents)'). We attempted to identify the protocol of each included trial, either in trials registers, publications of study designs, or both, and specified data in [Appendix 5](#).

We emailed authors of included trials to enquire as to whether they would be willing to answer questions regarding their trials. [Appendix 13](#) shows the results of this survey. We thereafter sought relevant missing information on the trial from the primary author(s) of the article, if required.

### Dealing with duplicate and companion publications

In the event of duplicate publications, companion documents, or multiple reports of a primary trial, we maximised yield of information by collating all available data and using the most complete data set aggregated across all known publications. Where

unclear, the publication reporting the longest follow-up associated with our primary or secondary outcomes obtained priority. We listed duplicate publications, companion documents or multiple reports of a primary trial as secondary references under the study ID of the included or excluded trial.

### Assessment of risk of bias in included studies

Two review authors (CAC, NDF) independently assessed the risk of bias of each included trial. We resolved disagreements by consensus, or by consultation with a third review author (DGP).

We assessed risk of bias using the tool of The Cochrane Collaboration (Higgins 2011a; Higgins 2011b). We used the following criteria.

- Random sequence generation (selection bias).
- Allocation concealment (selection bias).
- Blinding of participants and personnel (performance bias).
- Blinding of outcome assessment (detection bias).
- Incomplete outcome data (attrition bias).
- Selective reporting (reporting bias).
- Other potential sources of bias.

We judged 'Risk of bias' criteria as 'low risk', 'high risk', or 'unclear risk' and evaluated individual bias items as described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a). We have presented a 'Risk of bias' graph and a 'Risk of bias summary'. We assessed the impact of individual bias domains on trial results at the endpoint and trial levels. In case of high risk of selection bias, we would have marked all endpoints investigated in the associated trial as 'high risk'.

For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessors), we evaluated the risk of bias separately for each outcome (Hróbjartsson 2013). We noted whether outcomes were measured subjectively or objectively, for example if body weight was measured by participants or trial personnel.

We considered the implications of missing outcome data from individual participants per outcome such as high drop-out rates (for example above 15%) or disparate attrition rates (for example difference of 10% or more between trial arms).

We assessed outcome reporting bias by integrating the results of 'Examination of outcome reporting bias' ([Appendix 6](#)) and 'Matrix of study endpoints (publications and trial documents)' ([Appendix 5](#)) (Kirkham 2010). This analysis formed the basis for the judgement of selective reporting (reporting bias).

We defined the following endpoints as subjective outcome measures.

- Patient satisfaction.
- Hypoglycaemic episodes, depending on measurement.
- Adverse events other than hypoglycaemia, depending on measurement.

We defined the following endpoints as objective outcome measures.

- Time to resolution of DKA.



- All-cause mortality.
- Morbidity.
- Hypoglycaemic episodes, depending on measurement.
- Adverse events other than hypoglycaemia, depending on measurement.
- HbA1c.
- Socioeconomic effects.

### Measures of treatment effect

We expressed dichotomous data as odds ratios or risk ratios with 95% confidence intervals (CIs). We expressed continuous data as mean differences with 95% CIs. We planned to express time-to-event data as hazard ratios with 95% CIs.

### Unit of analysis issues

We took into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials, and multiple observations for the same outcome.

### Dealing with missing data

We obtained missing data from authors, if feasible, and carefully evaluated important numerical data such as screened, randomised participants as well as intention-to-treat and as-treated and per-protocol populations. We investigated attrition rates, (e.g. drop-outs, losses to follow-up, withdrawals), and we will critically appraise issues concerning missing data and imputation methods (e.g. last observation carried forward (LOCF)).

Where standard deviations for outcomes were not reported and we did not receive information from trial authors, we planned to impute these values by assuming the standard deviation of the missing outcome to be the average of the standard deviations from those studies where this information was reported. We wanted to investigate the impact of imputation on meta-analyses by means of sensitivity analysis.

### Assessment of heterogeneity

In the event of substantial clinical or methodological heterogeneity, we did not report trial results as the pooled effect estimate in a meta-analysis.

We identified heterogeneity (inconsistency) through visual inspection of the forest plots and by using a standard  $\chi^2$  test with a significance level of  $\alpha = 0.1$ . In view of the low power of this test, we also considered the  $I^2$  statistic, which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta-analysis (Higgins 2002; Higgins 2003); an  $I^2$  statistic of 75% or more indicates a considerable level of heterogeneity (Higgins 2011a).

Had we found heterogeneity, we would have attempted to determine possible reasons for it by examining individual trial and subgroup characteristics.

### Assessment of reporting biases

Had we included 10 trials or more investigating a particular outcome, we would have used funnel plots to assess small-study effects. Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small

trials), and publication bias. We therefore planned to interpret results carefully (Sterne 2011).

### Data synthesis

Unless there was good evidence for homogeneous effects across studies, we primarily summarised low risk of bias data by means of a random-effects model (Wood 2008). We interpreted random-effects meta-analyses with due consideration of the whole distribution of effects, ideally by presenting a prediction interval (Higgins 2009), which specifies a predicted range for the true treatment effect in an individual study (Riley 2011). In addition, we performed statistical analyses according to the statistical guidelines presented in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a).

### Quality of evidence

We have presented the overall quality of the evidence for each outcome according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, which takes into account issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results. Two review authors (CAC, NDF) independently rated the quality for each outcome. We have presented a summary of the evidence in 'Summary of findings' (SoF) tables, which provide key information about the best estimate of the magnitude of the effect, in relative terms and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and the rating of the overall confidence in effect estimates for each outcome. We created the SoF tables based on the methods described in the *Cochrane Handbook for Systematic Reviews of Interventions* by means of the table editor in Review Manager (RevMan), including Appendix 12 'Checklist to aid consistency and reproducibility of GRADE assessments' to help with standardisation of the 'Summary of findings' tables (Higgins 2011a; Meader 2014; RevMan 2014). Alternatively, we used the GRADEproGDT software and present evidence profile tables as an appendix (GRADEproGDT 2015). We have presented results on the outcomes as described in the [Types of outcome measures](#) section. If meta-analysis was not possible, we presented results in a narrative form in the SoF table.

### Subgroup analysis and investigation of heterogeneity

We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out subgroup analyses with investigation of interactions.

- Age.
- Pregnancy.
- Comorbidities.
- Precipitating factors (infection, poor adherence to diabetes treatment).
- Severity of DKA episode (mild, moderate, severe).

### Sensitivity analysis

We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting the analysis to the following.

- Published trials.

- Taking into account risk of bias, as specified in the [Assessment of risk of bias in included studies](#) section.
- Very long or large trials to establish the extent to which they dominate the results.
- Trials using the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other), or country.

We also tested the robustness of the results by repeating the analysis using different measures of effect size (RR, OR, etc.) and different statistical models (fixed-effect and random-effects models).

## RESULTS

### Description of studies


For a detailed description of the included trials, see [Characteristics of included studies](#), [Characteristics of excluded studies](#), and [Characteristics of studies awaiting classification](#).

### Results of the search

The electronic search strategies retrieved a total of 645 citations. After duplicates were excluded, two review authors (CAC, LCL) independently assessed the remaining titles and abstracts. We obtained the full text of 23 potentially relevant trials, seven of which we deemed potentially appropriate for inclusion in the analysis. Of these, two trials are awaiting classification, one trial was published as an abstract only, and another trial was registered in ClinicalTrials.gov with the status "This study has been completed", but no trial results were posted and no publication is available. We have provided information about these trials in [Characteristics of studies awaiting classification](#).

We have provided an adapted PRISMA flowchart of study selection, see [Figure 1](#).

**Figure 1. Study flow diagram.**



### Included studies

For a detailed description of the included studies, see [Characteristics of included studies](#). The following is a succinct overview.

### Source of data

A total of five trials (five publications) met the inclusion criteria. All five included trials were published as peer-reviewed original articles. All articles were published in English. We found no eligible trials from before the year 2004.

### Comparisons

All five included trials investigated the effects of a subcutaneous rapid-acting insulin analogues compared with intravenous regular insulin. Four trials used lispro ([Della Manna 2005](#); [Ersöz 2006](#); [Karoli 2011](#); [Umpierrez 2004a](#)), and one used aspart as a rapid acting insulin analogue ([Umpierrez 2004b](#)). No trial applied glulisine.

### Overview of study populations

The included trials evaluated a total of 201 participants, of which 110 received a subcutaneous rapid-acting insulin analogue and 91 received intravenous regular insulin. All randomised participants finished their assigned treatment.

## Study design

All included randomised controlled trials were of a parallel design and were performed in a single study centre. All trials compared a subcutaneous rapid-acting insulin analogue with intravenous regular insulin in an open-label fashion until resolution of the DKA episode. No trials specified blinding of outcome assessors. Trials were published from 2004 to 2011. Two trials were partly or entirely sponsored by the pharmaceutical industry (Umpierrez 2004a; Umpierrez 2004b).

## Settings

Trials were conducted in the USA (Umpierrez 2004a; Umpierrez 2004b), Brazil (Della Manna 2005), Turkey (Ersöz 2006), and India (Karoli 2011) (see [Characteristics of included studies](#) for details). In the US and Brazilian trials, participants were treated with subcutaneous insulin managed in regular medicine wards, in Umpierrez 2004a and Umpierrez 2004b, or in the emergency department, in Karoli 2011, and the participants treated with intravenous insulin were managed in the intensive care unit (Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). Two trials stated that the participants were managed in the emergency department (Della Manna 2005; Karoli 2011), and the Turkish trial did not provide details about the setting (Ersöz 2006).

## Participants

A total of 201 participants were randomised and exposed to trial insulins in the included studies. All five trials recruited people who had a DKA episode (Della Manna 2005; Ersöz 2006; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). One trial included paediatric and adolescent participants (60 DKA episodes in 46 participants) with a median age of 11 years (range 3 to 17 years) (Della Manna 2005); the other trials included either type 1 or type 2 diabetic adults with a DKA episode (Ersöz 2006; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). No trial specified the number of participants or percentages of participants with either type of diabetes. Three trials reported duration of diabetes (Ersöz 2006; Karoli 2011; Umpierrez 2004a); mean duration of diabetes in these trials ranged between 3.9 and 6.9 years. The mean age of participants ranged between 34 and 49 years in the trials with adults only (Ersöz 2006; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). Sixty per cent of participants came from low- to middle-income countries, and 27% to 76% were female. In one of the US trials, around 77% of participants were African American (Umpierrez 2004a). The other trials did not specify ethnic groups.

Four of the five trials reported a precipitating cause of the DKA episode (Della Manna 2005; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). Poor compliance with insulin therapy was the most common precipitating cause (54%). Other precipitating causes reported were infections (31%) and new-onset diabetes (15%). Two trials reported HbA1c at baseline (Ersöz 2006; Umpierrez 2004b). Mean HbA1c at baseline in these trials ranged between 11.4% and 13.9%.

All trials listed persistent hypotension as an exclusion criterion, but only the US trials clearly defined this (Umpierrez 2004a; Umpierrez 2004b). Three trials excluded people with acute myocardial ischaemia, end-stage renal disease, anasarca, and pregnancy (Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). Two trials excluded people with dementia (Umpierrez 2004a; Umpierrez

2004b), heart failure (Karoli 2011; Umpierrez 2004a), and with American Diabetes Association (ADA) criteria for severe DKA (Ersöz 2006; Karoli 2011). Other criteria used for excluding participants were surgery, use of glucocorticoid or immunosuppressive agents (Della Manna 2005), and the presence of hepatic failure (Umpierrez 2004b).

## Diagnosis

All trials specified diagnostic criteria for entry into the study. These criteria were consistent with the ADA criteria for mild or moderate DKA (ADA 2004). None of the included trials explicitly reported diagnostic criteria for diabetes mellitus.

## Interventions

None of the included trials reported treatment before the DKA episode. All of the trials compared subcutaneous rapid-acting insulin analogue injections every one to two hours with continuous intravenous infusions of regular insulin. Duration of interventions ranged from DKA diagnosis to DKA resolution.

Intravenous regular insulin regimens varied slightly across the trials. In three trials, the intravenous regular insulin bolus was 0.1 IU/kg, followed by continuous infusion given at 0.1 IU/kg/h until blood glucose decreased to < 250 mg/dL, and then continued at a lower dose (0.05 IU/kg/h until resolution of DKA) (Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). Ersöz 2006 used a slightly higher bolus dose of intravenous regular insulin of 0.15 IU/kg/h followed by "standard" intravenous regular insulin infusion. In the paediatric trial (Della Manna 2005), no bolus was used, and intravenous regular insulin infusion was given at 0.1 IU/kg/h until blood glucose decreased to < 250 mg/dL; thereafter 0.15 IU/kg regular insulin was given subcutaneously 30 minutes before stopping the intravenous line.

Subcutaneous rapid-acting insulin analogues injections varied across studies. Four trials used lispro at given dosages: injection regimens were either 0.15 IU every two hours without bolus (Della Manna 2005), or 0.075 IU/kg every hour, preceded by a bolus injection of intravenous regular insulin (0.15 IU/kg) (Ersöz 2006), or 0.1 IU/kg every hour, preceded by an initial subcutaneous bolus of insulin lispro (0.3 IU/kg) (Umpierrez 2004a), or initial subcutaneous bolus of insulin lispro (0.3 IU/kg), followed by 0.2 IU/kg one hour later and then 0.2 IU/kg every two hours (Karoli 2011). One trial used insulin aspart; subcutaneous insulin aspart was given as an initial dose of 0.3 IU/kg, followed by either 0.1 IU/kg every hour (group 1), or 0.2 IU/kg one hour later and every two hours (group 2) (Umpierrez 2004b). In one trial, when capillary blood glucose levels neared 250 mg/dL, insulin lispro was administered every four hours for the next 24 hours (Della Manna 2005).

## Concomitant interventions

Fluid replacement protocols were similar in all included trials. This was largely in agreement with guideline recommendations (ADA 2004). Isotonic (0.9%) saline was infused at a rate of 10 to 20 mL/kg/h or 500 to 1000 mL/h for the initial one to two hours. Subsequent fluid replacement was adapted depending on the participant's overall status and blood glucose levels until resolution of DKA. Potassium replacement was also in agreement with guideline recommendations (ADA 2004).

## Outcomes



Three trials did not explicitly specify a primary outcome (Della Manna 2005; Ersöz 2006; Karoli 2011). Four trials defined DKA by venous pH criteria (Della Manna 2005; Ersöz 2006; Umpierrez 2004a; Umpierrez 2004b), and one trial by arterial pH (Karoli 2011). Four trials used a serum bicarbonate criterion > 18 mmol/L as an endpoint (Ersöz 2006; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). The paediatric trial used a serum bicarbonate criterion > 15 mmol/L (Della Manna 2005). Notably, only one trial clearly stated blood glucose levels < 200 mg/dL as an endpoint (Ersöz 2006).

All trials reported data on adverse events in the form of hypoglycaemic episodes during therapy. Four trials defined the endpoint for this outcome as a plasma glucose  $\leq$  60 mg/dL (Della Manna 2005; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). In the trial by Ersöz 2006, the outcome measure of hypoglycaemia was not defined. All five trials reported on in-hospital mortality. Three trials reported length of hospital stay (Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). The paediatric trial investigated morbidity in the form of cases of cerebral oedema (Della Manna 2005), and Karoli 2011 described venous thrombosis,

adult respiratory distress syndrome, and hyperchloraemic acidosis events. One trial investigated total costs, measured as data on hospital charges (Umpierrez 2004a). No trial reported on patient satisfaction, adverse events other than hypoglycaemia, and change of HbA1c from baseline.

### Excluded studies


We excluded 16 trials after evaluation of the full publication. We have provided reasons for exclusion of studies in [Characteristics of excluded studies](#). The main reasons for exclusion were inappropriate interventions and non-randomised study design.

### Risk of bias in included studies

For details on risk of bias of included trials, see [Characteristics of included studies](#).

For an overview of review authors' judgements about each risk of bias item for individual trials and across all trials, see [Figure 2](#) and [Figure 3](#).

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials).**



**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the trial did not measure that particular outcome).**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias): Time to resolution of diabetic ketoacidosis	Blinding of participants and personnel (performance bias): All-cause mortality	Blinding of participants and personnel (performance bias): Hypoglycaemic episodes	Blinding of participants and personnel (performance bias): Morbidity	Blinding of participants and personnel (performance bias): Non-hypoglycaemic adverse events	Blinding of participants and personnel (performance bias): Patient satisfaction	Blinding of participants and personnel (performance bias): HbA1c	Blinding of participants and personnel (performance bias): Socioeconomic effects	Blinding of outcome assessment (detection bias): Time to resolution of diabetic ketoacidosis	Blinding of outcome assessment (detection bias): All-cause mortality	Blinding of outcome assessment (detection bias): Morbidity	Blinding of outcome assessment (detection bias): Hypoglycaemic episodes	Blinding of outcome assessment (detection bias): Non-hypoglycaemic adverse events	Blinding of outcome assessment (detection bias): Patient satisfaction	Blinding of outcome assessment (detection bias): HbA1c	Blinding of outcome assessment (detection bias): Socioeconomic effects	Incomplete outcome data (attrition bias): Time to resolution of diabetic ketoacidosis	Incomplete outcome data (attrition bias): All-cause mortality	Incomplete outcome data (attrition bias): Hypoglycaemic episodes	Incomplete outcome data (attrition bias): Morbidity	Incomplete outcome data (attrition bias): Non-hypoglycaemic adverse events	Incomplete outcome data (attrition bias): Patient satisfaction	Incomplete outcome data (attrition bias): HbA1c	Incomplete outcome data (attrition bias): Socioeconomic effects	Selective reporting (reporting bias)	Other bias
Della Manna 2005	?	?	+	+	?	+					?	+	+	?					+	?	?	?					?	+
Ersöz 2006	?	?	+	+	?						?	+		+					+	+	+						?	+
Karoli 2011	+	?	+	+	?	?				?	?	+	?	?				?	+	+	+	+				+	+	+
Umpierrez 2004a	+	?	+	+	?					?	?	+		?				?	+	+	+					+	+	?
Umpierrez 2004b	?	?	+	+	?					?	?	+		?				?	+	+	+					?	+	?

## Allocation

Reporting on the methods of randomisation and allocation concealment was poor in most of the trials. All trials were described as randomised, however the method of randomisation was adequately described in only two trials (Karoli 2011; Umpierrez 2004b). None of the included trials described allocation concealment.

## Blinding

The stated method of blinding was open in all five trials. No trial described blinding of outcome assessors. Given the nature of the interventions, participant and personnel blinding was not appropriate. However, this implied a high risk of performance bias for the outcome measure time to resolution of DKA.

## Incomplete outcome data

All five trials reported having complete data for all included participants.

## Selective reporting

No study protocol was available for the included trials. Reporting bias was unclear for two trials due to unclear reporting of outcome

data for time to resolution of DKA (Appendix 6) (Della Manna 2005; Ersöz 2006).

## Other potential sources of bias

Two publications reported commercial funding (Umpierrez 2004a; Umpierrez 2004b), a source of possible sponsor bias.

## Effects of interventions

See: [Summary of findings for the main comparison Subcutaneous insulin lispro versus intravenous regular insulin for diabetic ketoacidosis](#); [Summary of findings 2 Subcutaneous insulin aspart versus intravenous regular insulin for diabetic ketoacidosis](#)

## Baseline characteristics

For details of baseline characteristics, see [Appendix 3](#) and [Appendix 4](#).

## Subcutaneous rapid-acting insulin analogues versus intravenous infusion of regular insulin

Umpierrez 2004b was a three-arm trial investigating intravenous regular insulin versus subcutaneous insulin aspart, given in doses

one or two hours apart. In order to avoid a unit of analysis error, we used the one-hour group for all meta-analyses.

### Primary outcomes

#### Time to resolution of DKA

##### Lispro versus regular insulin (adults)

Two trials compared subcutaneous insulin lispro with intravenous regular insulin in adults with DKA (Karoli 2011; Umpierrez 2004a). Meta-analysis showed the following differences between the two groups: mean difference (MD) 0.2 h (95% confidence interval (CI) -1.7 to 2.1);  $P = 0.81$ ; 90 participants; 2 trials; very low-quality evidence; Analysis 1.1. There was a high risk of performance bias and an unclear risk of detection bias for both included trials (Karoli 2011; Umpierrez 2004a).

##### Lispro versus regular insulin (children)

One trial including 60 children compared subcutaneous insulin lispro with intravenous regular insulin (Della Manna 2005). In both groups, the time to reach a glucose level of 250 mg/dL or less was approximately six hours. However, metabolic acidosis and ketosis took longer to resolve in the subcutaneous insulin lispro group (for intravenous regular insulin the time was six hours after capillary glucose  $\leq 250$  mg/dL, and for subcutaneous insulin lispro this occurred "in the next 6-h interval" (Della Manna 2005)). The trial authors concluded that glycaemic control worsened when insulin lispro was spaced to every four hours, indicating that this was time was too long to maintain the insulin analogue action. In addition, children receiving insulin lispro were more likely to receive bicarbonate therapy. There was a high risk of performance bias, an unclear risk of detection bias, and an unclear risk of reporting bias for this included trial (Della Manna 2005).

##### Aspart versus regular insulin

One trial compared subcutaneous insulin aspart with intravenous regular insulin in an adult population (Umpierrez 2004b). There was the following difference between the two groups: MD -1 h (95% CI -3.2 to 1.2);  $P = 0.36$ ; 30 participants; 1 trial; very low-quality evidence; Analysis 2.1. There was a high risk of performance bias and an unclear risk of detection bias for this included trial (Umpierrez 2004b).

##### All-cause mortality

All five included trials reported that there were no deaths (4 trials with 156 participants evaluating insulin lispro; moderate-quality evidence; Analysis 1.1, and 1 trial with 45 participants evaluating insulin aspart (two different insulin aspart schemes in 15 participants each); low-quality evidence; Analysis 2.1). However, no trial was adequately powered to investigate all-cause mortality. There was an overall low risk of bias for this outcome measure.

##### Hypoglycaemic episodes

Information on hypoglycaemia was available from all included trials. Hypoglycaemia was mostly defined as a blood glucose level lower than 60 mg/dL (Della Manna 2005; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). One trial did not provide a definition of hypoglycaemia (Ersöz 2006).

##### Lispro versus regular insulin

Four trials reported hypoglycaemic episodes (Della Manna 2005; Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). Comparison of

insulin lispro versus regular insulin showed a risk ratio (RR) 0.59 (95% CI 0.23 to 1.52);  $P = 0.28$ ; 156 participants; 4 trials; low-quality evidence; Analysis 1.3. There was a high risk of performance bias and an unclear risk of detection bias for all included trials.

##### Aspart versus regular insulin

One trial including 45 participants compared subcutaneous insulin aspart with intravenous regular insulin in an adult population (Umpierrez 2004b). Insulin aspart versus regular insulin did not show marked differences in the number of hypoglycaemic episodes (1/15 in the insulin aspart given every hour group; 1/15 in the insulin aspart given every two hours group; and 1/15 in the regular insulin group. RR comparing one of the two insulin aspart groups versus the regular insulin group was 1.00 (95% CI 0.07 to 14.55);  $P = 1.00$ ; 30 participants; 1 trial; low-quality evidence; Analysis 2.3. There was a high risk of performance bias and an unclear risk of detection bias for the included trial.

### Secondary outcomes

#### Morbidity

Two trials investigating the effects of insulin lispro versus regular insulin reported some data on morbidity related to the sequelae of DKA. One paediatric trial reported morbidity in the form of cerebral oedema (Della Manna 2005). There were no cases of cerebral oedema, and no child had to be treated with mannitol. Karoli 2011 reported that none of the participants in either group developed complications such as venous thrombosis, adult respiratory distress syndrome, or hyperchloraemic acidosis.

#### Adverse events other than hypoglycaemia

No trials reported adverse events other than hypoglycaemia.

#### Patient satisfaction

No trial reported on patient satisfaction.

#### HbA1c

HbA1c values were available in two trials for verification of metabolic control (Ersöz 2006; Umpierrez 2004b). However, the differences in change of HbA1c from baseline to study endpoint were not reported.

#### Socioeconomic effects

Three of the trials performed in adults reported length of hospital stay (Karoli 2011; Umpierrez 2004a; Umpierrez 2004b). Comparing subcutaneous insulin lispro with intravenous regular insulin resulted in a MD of -0.4 days (95% CI -1 to 0.2);  $P = 0.22$ ; 90 participants; 2 trials; low-quality evidence; (Analysis 1.4) and between subcutaneous insulin aspart and intravenous regular insulin: MD -1.1 day (95% CI -3.3 to 1.1);  $P = 0.32$ ; 30 participants; 1 trial; low-quality evidence (Analysis 2.4).

One study addressed costs (Umpierrez 2004a). The study authors calculated that DKA treatment with subcutaneous insulin lispro in the non-intensive care unit setting was associated with 39% lower hospitalisation charges compared with regular insulin treatment in the intensive care unit (USD 8801 (SD USD 5549) versus USD 14,429 (SD USD 5243).

## Subgroup analyses

We did not perform subgroup analyses because there were not enough studies to estimate effects in various subgroups.

## Sensitivity analyses

We could not perform preplanned analyses excluding unpublished trials because we included only published studies in this review. We were unable to perform sensitivity analyses with regard to risk of bias because all studies were of high or unclear risk of bias in various domains.

## Assessment of reporting bias

We did not draw funnel plots due to limited number of studies ( $n = 5$ ).

## Ongoing studies

We did not identify ongoing randomised controlled trials.

## DISCUSSION

### Summary of main results

This systematic review analysed the evidence from all published randomised controlled trials (RCTs) of subcutaneous rapid-acting insulin analogues in the treatment of diabetic ketoacidosis (DKA). We included five trials with a total of 201 participants in this review. The results of our review suggest that there is no substantial difference in the time to resolution of DKA between the subcutaneous rapid-acting insulin analogues lispro or aspart and intravenous regular insulin in adult participants. In the one included trial that assessed the effects of insulin lispro in children and adolescents with DKA, the resolution of acidaemia took longer as compared to intravenous regular insulin; the authors attributed this slower resolution to the increased interval of injections at every four hours after the initial decline of blood glucose to less than 250 mg/dL.

In terms of hypoglycaemia and length of hospital stay, the results obtained with subcutaneous rapid-acting insulin analogues and regular insulin were comparable in both adults and children. No deaths occurred. Data on morbidity and socioeconomic effects were limited. None of the trials reported on adverse events other than hypoglycaemia, patient satisfaction, or glycosylated haemoglobin A1c.

### Overall completeness and applicability of evidence

The trials analysed in this review were conducted in four different countries, three of which could be considered as low- or middle-income countries. Notably, most participants representing the high-income Western region were of African-American ethnicity. Younger diabetic participants and children were underrepresented in our trial cohorts. Based on the inclusion criteria of the analysed trials, the results are most relevant to adults with a mild or moderate DKA episode due to poor compliance with diabetes therapy. This may reflect poor 'health literacy' and lack of comprehension of treatment plans, factors associated with socioeconomic deprivation in low- or middle-income countries. Regarding the interventions, rapid-acting insulin analogues like insulin lispro and insulin aspart are widely available for use in daily clinical practice.

## Quality of the evidence

The risk of bias across several domains was unclear for the majority of included studies. This was due mainly to there being insufficient information to permit judgement of either a low or high risk of bias, despite attempts to contact the trial authors. According to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the quality of the evidence was low or very low for most clinically important outcomes (see [Summary of findings for the main comparison](#); [Summary of findings 2](#)). The available data were thus too few and inconsistent to provide firm evidence about the effects of subcutaneous rapid-acting insulin analogues in people with DKA.

## Potential biases in the review process

We conducted our review according to the previously published protocol. Two review authors independently assessed all citations identified by our electronic search strategies. Likewise, two review authors conducted 'Risk of bias' assessment and data collection. There were no conflicts of interests.

We believe that our search for RCTs has been comprehensive. However, we cannot exclude the possibility that studies with negative findings remain unpublished. Also, we did not systematically search the grey literature.

## Agreements and disagreements with other studies or reviews

Our systematic review on subcutaneous rapid-acting insulin analogues for DKA is in agreement with previously published reviews, [Mazer 2009](#) and [Vincent 2013](#), and current guidelines on the management of a hyperglycaemic crisis in adults with diabetes; treatment with subcutaneous rapid-acting insulin analogues (lispro and aspart) appears as an alternative to the use of intravenous regular insulin in the treatment of mild and moderate DKA ([Kitabchi 2009](#)).

## AUTHORS' CONCLUSIONS

### Implications for practice

Our analyses suggest that, on the basis of mostly low- to very low-quality evidence, there are neither advantages nor disadvantages when comparing the effects of subcutaneous rapid-acting insulin analogues (insulin lispro, insulin aspart) versus intravenous regular insulin for treating DKA. These results are most relevant to adults with a mild or moderate DKA episode due to poor compliance with diabetes therapy.

### Implications for research

Due to the paucity of high-quality evidence from RCTs comparing insulin interventions for DKA, future trials have the potential to change our way of treating this debilitating and expensive condition.

Future RCTs should adequately report on the method of randomisation and treatment allocation concealment. Blinding of study participants, study personnel, and outcome assessors could be done by using double-dummy designs. Follow-up of participants should be longer, and trial authors should adhere to the intention-to-treat principle. In addition, outcome measures should include

patient satisfaction, morbidity, and socioeconomic effects. Finally, multicentre trials are desirable to ensure external validity.

## ACKNOWLEDGEMENTS

We thank Karla Bergerhoff and Maria-Inti Metzendorf, Trials Search Co-ordinators of the Cochrane Metabolic and Endocrine Disorders Group, for developing the electronic search strategies.



## REFERENCES

### References to studies included in this review

#### Della Manna 2005 {published data only}

Della Manna T, Steinmetz L, Campos PR, Farhat SC, Schvartsman C, Kuperman H, et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. *Diabetes Care* 2005;**28**(8):1856-61.

#### Ersöz 2006 {published data only}

Ersöz HO, Ukinc K, Köse M, Erem C, Gunduz A, Hacıhasanoglu AB, et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. *International Journal of Clinical Practice* 2006;**60**(4):429-33.

#### Karoli 2011 {published data only}

Karoli R, Fatima J, Salman T, Sandhu S, Shankar R. Managing diabetic ketoacidosis in non-intensive care unit setting: Role of insulin analogs. *Indian Journal of Pharmacology* 2011;**43**(4):398-401.

#### Umpierrez 2004a {published data only}

Umpierrez GE, Latif K, Stoeve J, Cuervo R, Park L, Freire AX, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. *American Journal of Medicine* 2004;**117**(5):291-6.

#### Umpierrez 2004b {published data only}

Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. *Diabetes Care* 2004;**27**(8):1873-8.

### References to studies excluded from this review

#### Adesina 2011 {published data only}

Adesina OF, Kolawole BA, Ikem RT, Adebayo OJ, Soyoye DO. Comparison of lispro insulin and regular insulin in the management of hyperglycaemic emergencies. *African Journal of Medicine and Medical Sciences* 2011;**40**:59-66.

#### Armor 2011 {published data only}

Armor B, Harrison D, Lawler F. Assessment of the clinical outcome of a symptom-based outpatient hyperglycemia protocol. *Diabetes Therapy* 2011;**2**:67-80.

#### Attia 1998 {published data only}

Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. *Diabetes Care* 1998;**5**:817-21.

#### Fisher 1977 {published data only}

Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. *The New England Journal of Medicine* 1977;**297**(5):238-41.

#### Hsia 2011 {published data only}

Hsia E, Seggelke S, Draznin B. Novel insulin infusion protocol: Subcutaneous administration of long-acting insulin during insulin infusion prevents rebound hyperglycemia. *Diabetes* 2011;**60**:A262.

#### Kadowaki 2010 {published data only}

Kadowaki T, Nishida T, Kaku K. 28-week, randomised, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes. *Journal of Diabetes Investigation* 2010;**1**(3):103-10.

#### Liu 2006 {published data only}

Liu J, Jia Z, Zhang B, Hong LV, Zhang G, Tan B, et al. Insulin pump in the treatment of diabetic ketoacidosis. *Chinese Journal of Emergency Medicine* 2006;**15**:460-1.

#### NCT00467246 {unpublished data only}

NCT00467246. Sub-cutaneous insulin in hyperglycaemic emergencies. <https://www.clinicaltrials.gov/ct2/show/NCT00467246> (last accessed 4 December 2015).

#### NCT01365793 {unpublished data only}

NCT01365793. Randomized control trial of fluid therapy for pediatric diabetic ketoacidosis. <https://www.clinicaltrials.gov/ct2/show/NCT01365793> (last accessed 4 December 2015).

#### NCT02006342 {unpublished data only}

NCT02006342. Effectiveness of subcutaneous glargine on the time to closure of the anion gap in patients presenting to the emergency department with diabetic keto-acidosis (GT-COG). <https://www.clinicaltrials.gov/ct2/show/NCT02006342> (accessed 4 December 2015).

#### Philotheou 2011 {published data only}

Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Souhami E, Danne T. Comparable efficacy and safety of insulin glulisine and insulin lispro when given aspart of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type1 diabetes. *Diabetes Technology & Therapeutics* 2011;**3**:327-34.

#### Savoldelli 2010 {published data only}

Savoldelli RD, Farhat SC, Manna TD. Alternative management of diabetic ketoacidosis in a Brazilian pediatric emergency department. *Diabetology & Metabolic Syndrome* 2010;**2**:41.

#### Umpierrez 2009 {published data only}

Umpierrez GE, Jones S, Smiley D, Mulligan P, Keyler T, Temponi A, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. *Diabetes Care* 2009;**7**:1164-9.

#### Vincent 2013 {published data only}

Vincent M, Nobécourt E. Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: a review of the current evidence from clinical studies. *Diabetes & Metabolism* 2013;**39**(4):299-305.

**Weinzimer 2008** {published data only}

Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. *Diabetes Care* 2008;**31**(2):210-5.

**Yanai 2011** {published data only}

Yanai H, Adachi H, Hamasaki H. Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. *Diabetes Care* 2011;**34**(6):e108.

**References to studies awaiting assessment**
**El Ebrashy 2010** {published and unpublished data}

El Ebrashy I, El Hefnawy MHMF, Basyouni A, Mahfouz H. Subcutaneous use of rapid insulin analog: an alternative treatment for patients with mild to moderate diabetic ketoacidosis. *Pediatric Diabetes* 2010;**11**(Suppl 14):32 (O/6/FRI/01).

**NCT00920725** {unpublished data only}

NCT00920725. Subcutaneous aspart insulin to treat diabetic ketoacidosis (DKA) and beta-hydroxybutyrate testing in DKA. <https://www.clinicaltrials.gov/ct2/show/NCT00920725> (last accessed 4 December 2015).

**Additional references**
**ADA 1999**

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1999;**22**(Suppl 1):S5-19.

**ADA 2004**

American Diabetes Association. Hyperglycemic crises in diabetes. *Diabetes Care* 2004;**27**(Suppl 1):S94-102.

**ADA 2008**

American Diabetes Association. Standards of medical care in diabetes - 2008. *Diabetes Care* 2008;**31**(Suppl 1):S12-54. [PUBMED: 18165335]

**Alberti 1973**

Alberti KG, Hockaday TD, Turner RC. Small doses of intramuscular insulin in the treatment of diabetic "coma". *The Lancet* 1973;**2**(7828):515-22.

**Anderson 2004**

Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, et al. Development and validation of the insulin treatment satisfaction questionnaire. *Clinical Therapeutics* 2004;**26**(4):565-78.

**Basu 1993**

Basu A, Close CF, Jenkins D, Krentz AJ, Nattrass M, Wright AD. Persisting mortality in diabetic ketoacidosis. *Diabetic Medicine* 1993;**10**:282-4.

**Beller 2013**

Beller EM, Chen JK, Wang UL, Glasziou PP. Are systematic reviews up-to-date at the time of publication?. *Systematic Reviews* 2013;**2**(1):36.

**Dave 2004**

Dave J, Chatterjee S, Davies M, Higgins K, Morjaria H, McNally P, et al. Evaluation of admissions and management of diabetic ketoacidosis in a large teaching hospital. *Practical Diabetes International* 2004;**21**(4):149-53.

**Faich 1983**

Faich GA, Fishbein HA, Ellis SE. The epidemiology of diabetic acidosis: a population-based study. *American Journal of Epidemiology* 1983;**117**(5):551-8.

**Hemkens 2009**

Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. *Diabetologia* 2009;**52**(9):1732-44.

**Higgins 2002**

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**:1539-58.

**Higgins 2003**

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. *BMJ* 2003;**327**:557-60.

**Higgins 2009**

Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 2009;**172**(1):137-59.

**Higgins 2011a**

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Higgins 2011b**

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. *BMJ* 2011;**343**:d5928.

**Home 2000**

Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. *Diabetic Medicine* 2000;**17**(11):762-70.

**Home 2012**

Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity & Metabolism* 2012;**14**(9):780-8.

**Howey 1995**

Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, et al. [Lys(B28), Pro(B29)]-human insulin:



effect of injection time on postprandial glycemia. *Clinical Pharmacology and Therapeutics* 1995;**58**(4):459-69.

### Hróbjartsson 2013

Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. *Canadian Medical Association Journal* 2013;**185**(4):E201-11.

### Johnson 1980

Johnson DD, Palumbo PJ, Chu CP. Diabetic ketoacidosis in a community-based population. *Mayo Clinic Proceedings* 1980;**55**(2):83-8.

### Kim 2007

Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States. *Diabetes Care* 2007;**30**(5):1281-2.

### Kirkham 2010

Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ* 2010;**340**:c365. [DOI: [10.1136/bmj.c365](https://doi.org/10.1136/bmj.c365)]

### Kitabchi 2001

Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JL, et al. Management of hyperglycemic crises in patients with diabetes. *Diabetes Care* 2001;**24**:131-53.

### Kitabchi 2009

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care* 2009;**32**(7):1335-43.

### Kurtzhals 2000

Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. *Diabetes* 2000;**49**(6):999-1005.

### Liberati 2009

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. *PLoS Medicine* 2009;**6**(7):1-28. [DOI: [10.1371/journal.pmed.1000100](https://doi.org/10.1371/journal.pmed.1000100)]

### Luzi 1988

Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo RA. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. *Diabetes* 1988;**37**(11):1470-7.

### Malone 1992

Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. *Journal of the American Geriatrics Society* 1992;**40**(11):1100-4.

### Mathiesen 2007

Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, et al. Maternal glycaemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. *Diabetes Care* 2007;**30**(4):771-6.

### Mazer 2009

Mazer M, Chen E. Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis?. *Annals of Emergency Medicine* 2009;**53**(2):259-63.

### Meador 2014

Meador N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. *Systematic Reviews* 2014;**3**:82.

### Muir 2004

Muir AB, Quisling RG, Yang MC, Rosenbloom AL. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. *Diabetes Care* 2004;**27**(7):1541-6.

### Nyenwe 2011

Nyenwe EA, Kitabchi AE. Evidence-based management of hyperglycemic emergencies in diabetes mellitus. *Diabetes Research and Clinical Practice* 2011;**94**(3):340-51.

### Rayman 2007

Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. *Diabetes Research and Clinical Practice* 2007;**76**(2):304-12.

### RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

### Riley 2011

Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ* 2011;**342**:d549.

### Roach 2008

Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. *Clinical Pharmacokinetics* 2008;**47**(9):595-610.

### Savage 2011

Savage MW, Dhatriya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. *Diabetic Medicine* 2011;**28**(5):508-15.

### Siebenhofer 2006

Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. *Cochrane Database of Systematic Reviews* 2006, Issue 2. [DOI: [10.1002/14651858.CD003287](https://doi.org/10.1002/14651858.CD003287)]

**Sterne 2011**

Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. *BMJ* 2011;**343**:d4002.

**Warner 1998**

Warner DP, McKinney PA, Law GR, Bodansky HJ. Mortality and diabetes from a population based study in Yorkshire. *Archives of Disease in Childhood* 1998;**78**:435-8.

**WHO 1998**

Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabetic Medicine* 1998;**15**:539-53.

**Wood 2008**

Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ* 2008;**336**(7644):601-5.

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

**Della Manna 2005**

Methods	<b>Parallel randomised controlled trial</b>  <b>Randomisation ratio:</b> 1:1  <b>Superiority design</b>
Participants	<b>Inclusion criteria:</b> DKA, blood glucose > 300 mg/dL, pH < 7.3, and/or bicarbonate < 15 mmol/L, and > + ketonuria  <b>Exclusion criteria:</b> surgery, use of glucocorticoid or immunosuppressive agents  <b>Diagnostic criteria:</b> ADA criteria for DKA  <b>Causes of DKA (n) - (subcutaneous insulin/intravenous insulin):</b> <ul style="list-style-type: none"> <li>Excessive food intake: 13/13</li> <li>Infection: 8/4</li> <li>Missed injection: 10/5</li> <li>New onset diabetes: 6/5</li> <li>Unidentified: 1/4</li> </ul>
Interventions	<b>Number of study centres:</b> 1  <b>Treatment before study:</b> not stated  Group 1: s.c. insulin lispro. 0.15 IU/kg every 2 h until blood glucose < 250 mg/dL, then every 4 h for the next 24 h (n = 30)  Group 2: i.v. regular insulin. 0.1 IU/kg/h, continuous infusion until blood glucose < 250 mg/dL, and then 0.15 IU/kg subcutaneously every 4 h for 24 h (n = 30)
Outcomes	<b>Composite outcome measures reported:</b> no
Study details	<b>Run-in period:</b> no  <b>Study terminated before regular end (for benefit/because of adverse events):</b> no
Publication details	<b>Language of publication:</b> English  <b>Non-commercial funding:</b> Fundacao de Amparo à Pesquisa do Estado de Sao Paulo grant (FAPESP 00/09682-7)  <b>Publication status:</b> peer-reviewed journal

**Della Manna 2005** (Continued)

Stated aim for study	Quote from publication: "... to compare the efficacy of a subcutaneous fast-acting analog (lispro) with continuous intravenous regular insulin (CIRI) in the treatment of pediatric DKA"	
Notes	Study authors randomised episodes of DKA, not participants	
<b>Risk of bias</b>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote from publication: "Of the 60 DKA episodes, 30 were randomised to treatment with a subcutaneous fast-acting insulin analog (lispro) and the other 30 were randomised to treatment with CIRI"  Comment: no detailed information
Allocation concealment (selection bias)	Unclear risk	Comment: no detailed information
Blinding of participants and personnel (performance bias) Time to resolution of diabetic ketoacidosis	High risk	Comment: participants and personnel were probably unblinded
Blinding of participants and personnel (performance bias) All-cause mortality	Low risk	Comment: study personnel/participants probably not blinded, but outcome measurement unlikely to be influenced by the lack of blinding
Blinding of participants and personnel (performance bias) Hypoglycaemic episodes	Unclear risk	Comment: study personnel/participants probably not blinded
Blinding of participants and personnel (performance bias) Morbidity	Low risk	Comment: study personnel/participants probably not blinded, but outcome measurement unlikely to be influenced by the lack of blinding
Blinding of outcome assessment (detection bias) Time to resolution of diabetic ketoacidosis	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) All-cause mortality	Low risk	Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding
Blinding of outcome assessment (detection bias) Morbidity	Low risk	Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding
Blinding of outcome assessment (detection bias) Hypoglycaemic episodes	Unclear risk	Comment: no detailed information
Incomplete outcome data (attrition bias)	Low risk	Comment: reasons for dropouts explained

**Della Manna 2005** (Continued)

Time to resolution of diabetic ketoacidosis

Incomplete outcome data (attrition bias) All-cause mortality	Unclear risk	Comment: DKA occurrences randomised, not participants (unclear which participants had only 1 DKA)
Incomplete outcome data (attrition bias) Hypoglycaemic episodes	Unclear risk	Comment: DKA occurrences randomised, not participants (unclear which participants had only 1 DKA)
Incomplete outcome data (attrition bias) Morbidity	Unclear risk	Comment: DKA occurrences randomised, not participants (unclear which participants had only 1 DKA)
Selective reporting (reporting bias)	Unclear risk	Comment: possible outcome reporting bias for time to resolution of DKA (see <a href="#">Appendix 6</a> )
Other bias	Low risk	Comment: none detected

**Ersöz 2006**

Methods	<b>Parallel randomised controlled trial</b>  <b>Randomisation ratio:</b> 1:1  <b>Superiority design</b>
Participants	<b>Inclusion criteria:</b> DKA (mild or moderate only), serum blood glucose > 250 mg/dL, arterial pH < 7.3, bicarbonate < 15 mmol/L, beta-hydroxybutyrate > 1.6 mmol/L, ketonuria  <b>Exclusion criteria:</b> plasma glucose > 600 mg/dL, pH < 7.0, bicarbonate < 10 mmol/L, persistent hypotension, hypothermia, severe concomitant illness  <b>Diagnostic criteria:</b> ADA criteria for DKA  <b>Causes of DKA:</b> new onset diabetes (3 subcutaneous insulin lispro/2 intravenous regular insulin)
Interventions	<b>Number of study centres:</b> 1  <b>Treatment before study:</b> not stated
Outcomes	<b>Composite outcome measures reported:</b> no
Study details	<b>Run-in period:</b> no  <b>Study terminated before regular end (for benefit/because of adverse events):</b> no
Publication details	<b>Language of publication:</b> English  <b>Commercial funding/non-commercial funding/other funding:</b> no  <b>Publication status:</b> peer-reviewed journal
Stated aim for study	Quote from publication: "... to evaluate the efficacy and safety of hourly SC insulin lispro administration in the treatment of DKA in comparison with standard IV regular insulin treatment"
Notes	-

**Ersöz 2006** (Continued)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote from publication: "The patients were randomly assigned into two groups"  Comment: no detailed information
Allocation concealment (selection bias)	Unclear risk	Comment: no detailed information
Blinding of participants and personnel (performance bias) Time to resolution of diabetic ketoacidosis	High risk	Comment: participants and personnel were probably not blinded
Blinding of participants and personnel (performance bias) All-cause mortality	Low risk	Comment: study personnel/participants probably not blinded, but outcome measurement unlikely to be influenced by the lack of blinding
Blinding of participants and personnel (performance bias) Hypoglycaemic episodes	Unclear risk	Comment: study personnel/participants probably not blinded, outcome measurement not defined
Blinding of outcome assessment (detection bias) Time to resolution of diabetic ketoacidosis	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) All-cause mortality	Low risk	Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding
Blinding of outcome assessment (detection bias) Hypoglycaemic episodes	Low risk	Comment: no detailed information, but outcome measurement unlikely to be influenced by the lack of blinding
Incomplete outcome data (attrition bias) Time to resolution of diabetic ketoacidosis	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias) All-cause mortality	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias) Hypoglycaemic episodes	Low risk	Comment: all randomised participants completed the study
Selective reporting (reporting bias)	Unclear risk	Comment: possible outcome reporting bias for time to resolution of DKA (see <a href="#">Appendix 6</a> )
Other bias	Low risk	Comment: none detected

## Karoli 2011

Methods	<p><b>Parallel randomised controlled trial</b></p> <p><b>Randomisation ratio:</b> 1:1</p> <p><b>Superiority design</b></p>
Participants	<p><b>Inclusion criteria:</b> DKA (mild or moderate only, ADA criteria)</p> <p><b>Exclusion criteria:</b> severe DKA and those requiring ICU admission, loss of consciousness, acute myocardial ischaemia, congestive heart failure, end-stage renal disease, anasarca, pregnancy, serious co-morbidities, persistent hypotension</p> <p><b>Diagnostic criteria:</b> ADA criteria for DKA</p> <p><b>Causes of DKA</b> (% regular intravenous insulin/subcutaneous insulin lispro)</p> <ul style="list-style-type: none"> <li>• Infection: 56/52</li> <li>• Poor compliance: 32/40</li> <li>• New onset diabetes: 12/8</li> </ul>
Interventions	<p>Number of study centres: 1</p> <p>Treatment before study: not stated</p> <p>Titration period: no</p>
Outcomes	<b>Composite outcome measures reported:</b> no
Study details	<p><b>Run-in period:</b> no</p> <p><b>Study terminated before regular end (for benefit/because of adverse events):</b> no</p>
Publication details	<p><b>Language of publication:</b> English</p> <p><b>Commercial funding/non-commercial funding/other funding:</b> none</p> <p><b>Publication status:</b> peer-reviewed journal</p>
Stated aim for study	Quote from publication: "... to compare the efficacy of insulin lispro subcutaneous 2 hourly in patients of mild to moderate DKA with standard intravenous regular insulin"
Notes	-

### Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote from publication: "The study patients were randomised in emergency department following a computer generated randomisation table in two groups"
Allocation concealment (selection bias)	Unclear risk	Comment: no detailed information
Blinding of participants and personnel (performance bias)	High risk	<p>Quote from publication: "In this prospective, randomised and open trial ..."</p> <p>Comment: participants and personnel were unblinded (open trial)</p>

**Karoli 2011** (Continued)

Time to resolution of diabetic ketoacidosis

Blinding of participants and personnel (performance bias) All-cause mortality	Low risk	Quote from publication: "In this prospective, randomised and open trial ..."  Comment: participants and study personnel not blinded, but outcome measurement not likely to be influenced by the lack of blinding
Blinding of participants and personnel (performance bias) Hypoglycaemic episodes	Unclear risk	Quote from publication: "In this prospective, randomised and open trial ..."  Comment: participants and personnel were unblinded (open trial)
Blinding of participants and personnel (performance bias) Morbidity	Unclear risk	Quote from publication: "In this prospective, randomised and open trial ..."  Comment: participants and personnel were unblinded (open trial)
Blinding of participants and personnel (performance bias) Socioeconomic effects	Unclear risk	Quote from publication: "In this prospective, randomised and open trial ..."  Comment: participants and personnel were unblinded (open trial)
Blinding of outcome assessment (detection bias) Time to resolution of diabetic ketoacidosis	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) All-cause mortality	Low risk	Comment: no detailed information, outcome not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) Morbidity	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) Hypoglycaemic episodes	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) Socioeconomic effects	Unclear risk	Comment: no detailed information
Incomplete outcome data (attrition bias) Time to resolution of diabetic ketoacidosis	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias) All-cause mortality	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias) Hypoglycaemic episodes	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias)	Low risk	Comment: all randomised participants completed the study

**Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis (Review)**

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.

## Karoli 2011 (Continued)

### Morbidity

Incomplete outcome data (attrition bias) Socioeconomic effects	Low risk	Comment: all randomised participants completed the study
Selective reporting (reporting bias)	Low risk	Comment: none detected
Other bias	Low risk	Comment: none detected

## Umpierrez 2004b

Methods	<b>Parallel randomised controlled trial</b>  <b>Randomisation ratio: 1:1:1</b>  <b>Superiority design</b>
Participants	<b>Inclusion criteria:</b> "Uncomplicated DKA" defined by a plasma glucose level > 250 mg/dL, serum bicarbonate level < 15 mEq/L, venous pH < 7.3, serum ketone level at a dilution of greater than or equal to 1:4 by nitroprusside reaction, or serum beta-hydroxybutyrate level > 3.0 mmol/L  <b>Exclusion criteria:</b> persistent hypotension after the administration of 1 liter of normal saline (systolic blood pressure < 80 mmHg), acute myocardial ischaemia, end-stage renal or hepatic failure, anasarca, dementia, or pregnancy  <b>Diagnostic criteria:</b> ADA criteria for DKA  <b>Causes of DKA (%):</b> poor compliance: 53 (s.c. insulin aspart, every hour)/60 (s.c. insulin aspart, every 2 hours)/60 (i.v. regular insulin); new onset diabetes: 20 (s.c. insulin aspart, every hour)/20 (s.c. insulin aspart, every 2 hours)/13 (i.v. regular insulin)
Interventions	<b>Number of study centres:</b> 1  <b>Treatment before study:</b> not stated  <b>Titration period:</b> no
Outcomes	<b>Composite outcome measures reported:</b> no
Study details	<b>Run-in period:</b> no  <b>Study terminated before regular end (for benefit/because of adverse events):</b> no
Publication details	<b>Language of publication:</b> English  <b>Commercial funding:</b> unrestricted grant from Novo Nordisk; <b>non-commercial funding:</b> United States Public Health Services/National Institutes of Health grant (RR00211; General Clinical Research Center)  <b>Publication status:</b> peer-reviewed journal
Stated aim for study	Quote from publication: "We compared the efficacy and safety of aspart insulin given subcutaneously at different time intervals to a standard low-dose intravenous (IV) infusion protocol of regular insulin in patients with uncomplicated diabetic ketoacidosis (DKA)"
Notes	-



**Umpierrez 2004b** (Continued)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote from publication: "Patients were randomly assigned in the emergency department to receive SC aspart insulin every hour (SC-1h, n15) or every 2 h (SC-2h, n15), or to receive IV regular insulin (n15)"  Comment: insufficient information about the sequence generation process
Allocation concealment (selection bias)	Unclear risk	Comment: no detailed information
Blinding of participants and personnel (performance bias) Time to resolution of diabetic ketoacidosis	High risk	Quote from publication: "In this prospective, randomised, open trial ..."  Comment: participants and personnel were unblinded
Blinding of participants and personnel (performance bias) All-cause mortality	Low risk	Quote from publication: "In this prospective, randomised, open trial ..."  Comment: outcome measurement not likely to be influenced by the lack of blinding
Blinding of participants and personnel (performance bias) Hypoglycaemic episodes	Unclear risk	Quote from publication: "In this prospective, randomised, open trial ..."  Comment: unclear whether outcome was influenced by lack of blinding
Blinding of participants and personnel (performance bias) Socioeconomic effects	Unclear risk	Quote from publication: "In this prospective, randomised, open trial ..."  Comment: unclear whether outcome was influenced by lack of blinding
Blinding of outcome assessment (detection bias) Time to resolution of diabetic ketoacidosis	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) All-cause mortality	Low risk	Comment: outcome measurement not likely to be influenced by the lack of blinding
Blinding of outcome assessment (detection bias) Hypoglycaemic episodes	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) Socioeconomic effects	Unclear risk	Comment: no detailed information
Incomplete outcome data (attrition bias) Time to resolution of diabetic ketoacidosis	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias)	Low risk	Comment: all randomised participants completed the study

**Umpierrez 2004b** (Continued)

All-cause mortality

Incomplete outcome data (attrition bias) Hypoglycaemic episodes	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias) Socioeconomic effects	Unclear risk	Comment: all randomised participants completed the study
Selective reporting (reporting bias)	Low risk	Comment: none detected
Other bias	Unclear risk	Comment: possible sponsor bias (unrestrictive grant from Novo Nordisk)

**Umpierrez 2004a**

Methods	<b>Parallel randomised controlled trial</b>  <b>Randomisation ratio:</b> 1:1  <b>Superiority design</b>
Participants	<b>Inclusion criteria:</b> plasma glucose level > 250 mg/dL, serum bicarbonate level < 15 mEq/L, venous pH < 7.3, serum ketone level, beta-hydroxybutyrate > 3 mmol/L  <b>Exclusion criteria:</b> persistent hypotension after the administration of 1 liter of normal saline (systolic blood pressure < 80 mmHg), acute myocardial ischaemia, heart failure, end-stage renal disease, anasarca, dementia, or pregnancy  <b>Diagnostic criteria:</b> ADA criteria for DKA  <b>Causes of DKA (%):</b> poor compliance: 60 (subcutaneous insulin lispro)/70 (intravenous regular insulin)
Interventions	<b>Number of study centres:</b> 1  <b>Treatment before study:</b> not stated  <b>Titration period:</b> no
Outcomes	<b>Composite outcome measures reported:</b> no
Study details	<b>Run-in period:</b> no  <b>Study terminated before regular end (for benefit/because of adverse events):</b> no
Publication details	<b>Language of publication:</b> English  <b>Commercial funding:</b> unrestricted grant from Eli Lilly; <b>non-commercial funding:</b> United States Public Health Services grant (RR00211)  <b>Publication status:</b> peer-reviewed journal
Stated aim for study	Quote from publication: "To compare the efficacy and safety of subcutaneous insulin lispro with that of low-dose continuous intravenous regular insulin in the treatment of patients with uncomplicated diabetic ketoacidosis"
Notes	-

**Umpierrez 2004a** (Continued)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote from publication: "Patients were assigned in the emergency department to receive subcutaneous insulin lispro or intravenous regular insulin following a computer-generated randomisation table"
Allocation concealment (selection bias)	Unclear risk	Comment: no detailed information
Blinding of participants and personnel (performance bias) Time to resolution of diabetic ketoacidosis	High risk	Quote from publication: "open trial" Comment: participants and personnel were unblinded (open trial)
Blinding of participants and personnel (performance bias) All-cause mortality	Low risk	Comment: study personnel not blinded, but outcome measurement not likely to be influenced by the lack of blinding of outcome assessment
Blinding of participants and personnel (performance bias) Hypoglycaemic episodes	Unclear risk	Comment: unclear whether outcome was influenced by lack of blinding
Blinding of participants and personnel (performance bias) Socioeconomic effects	Unclear risk	Quote from publication: "open trial" Comment: participants and personnel were unblinded (open trial)
Blinding of outcome assessment (detection bias) Time to resolution of diabetic ketoacidosis	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) All-cause mortality	Low risk	Comment: no information on blinding of outcome assessment, but outcome measurement not likely to be influenced
Blinding of outcome assessment (detection bias) Hypoglycaemic episodes	Unclear risk	Comment: no detailed information
Blinding of outcome assessment (detection bias) Socioeconomic effects	Unclear risk	Comment: no detailed information
Incomplete outcome data (attrition bias) Time to resolution of diabetic ketoacidosis	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias) All-cause mortality	Low risk	Comment: all randomised participants completed the study

**Umpierrez 2004a** *(Continued)*

Incomplete outcome data (attrition bias) Hypoglycaemic episodes	Low risk	Comment: all randomised participants completed the study
Incomplete outcome data (attrition bias) Socioeconomic effects	Low risk	Comment: all randomised participants completed the study
Selective reporting (reporting bias)	Low risk	Comment: none detected
Other bias	Unclear risk	Comment: possible sponsor bias (unrestrictive grant from Eli Lilly)

Note: where the judgement is 'unclear risk' and the description is blank, the trial did not report that particular outcome  
ADA: American Diabetes Association; DKA: diabetic ketoacidosis; ICU: intensive care unit; i.v.: intravenous; s.c.: subcutaneous

**Characteristics of excluded studies** *[ordered by study ID]*

Study	Reason for exclusion
<a href="#">Adesina 2011</a>	Intervention not relevant (insulin therapy was by the intramuscular route)
<a href="#">Armor 2011</a>	Not an RCT (case series)
<a href="#">Attia 1998</a>	Not aimed at treating DKA (well-controlled insulin-dependent diabetes mellitus)
<a href="#">Fisher 1977</a>	Intervention not relevant (regular insulin by various routes)
<a href="#">Hsia 2011</a>	Intervention not relevant (s.c. administration of long-acting insulins)
<a href="#">Kadowaki 2010</a>	Not aimed at treating DKA
<a href="#">Liu 2006</a>	Intervention not relevant (s.c. and i.v. infusion of regular insulin)
<a href="#">NCT00467246</a>	Intervention not relevant (insulin levemir)
<a href="#">NCT01365793</a>	Intervention not relevant (fluid therapy)
<a href="#">NCT02006342</a>	Intervention not relevant (s.c. insulin glargine)
<a href="#">Philotheou 2011</a>	Not aimed at treating DKA
<a href="#">Savoldelli 2010</a>	Not an RCT (review article)
<a href="#">Umpierrez 2009</a>	Intervention not relevant (i.v. regular or i.v. glulisine insulin)
<a href="#">Vincent 2013</a>	Not an RCT (review article)
<a href="#">Weinzimer 2008</a>	Not aimed at treating DKA
<a href="#">Yanai 2011</a>	Not an RCT (case report)

DKA: diabetic ketoacidosis; i.v.: intravenous; RCT: randomised controlled trial; s.c.: subcutaneous

## Characteristics of studies awaiting assessment *[ordered by study ID]*

### El Ebrashy 2010

Methods	Randomised controlled trial
Participants	80 people with DKA
Interventions	Group 1: regular insulin infusion (n = 20) Group 2: s.c. rapid-acting insulin analogue aspart every 2 hours (n = 20) Group 3: s.c. rapid-acting insulin analogue aspart every hour (n = 20) Group 4: rapid-acting insulin analogue by subcutaneous insulin pump (n = 20)
Outcomes	Time to resolution of DKA
Study details	<b>Intervention model:</b> factorial design <b>Masking:</b> not stated <b>Primary purpose:</b> treatment
Publication details	Conference abstract
Stated aim of study	To look for technical simplification and economic efficiency in the treatment of DKA with s.c. use of rapid-acting insulin analogue and to compare its use with regular i.v. insulin treatment
Notes	No outcome data reported in abstract (authors contacted by email; no reply received)

### NCT00920725

Methods	Randomised controlled trial
Participants	Adults with DKA
Interventions	Group 1: s.c. insulin aspart every 2 hours Group 2: i.v. regular insulin Group 3: i.v. insulin aspart (NovoLog)
Outcomes	Hours to resolution of ketoacidosis as defined as beta-hydroxybutyrate < 0.6 Hours to achieve blood glucose less than 200 mg/dL
Study details	<b>Intervention model:</b> parallel assignment <b>Masking:</b> open label <b>Primary purpose:</b> treatment
Publication details	<b>Study start date:</b> January 2005 <b>Study completion date:</b> December 2007 <b>Primary completion date:</b> July 2007 (final data collection date for primary outcome measure) Study not yet published (authors contacted by email; no reply received yet)

**NCT00920725** (Continued)

Stated aim of study	To determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine whether it is useful to monitor beta-hydroxybutyrate during treatment of a diabetic crisis
Notes	<b>Responsible party:</b> David Baldwin, MD. Rush University Medical Center Chicago, Illinois, United States, 60612  Registered in ClinicalTrials.gov. Study completed, no results published




DKA: diabetic ketoacidosis; i.v.: intravenous; s.c.: subcutaneous

## DATA AND ANALYSES


### Comparison 1. Insulin lispro versus regular insulin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Time to resolution of diabetic ketoacidosis	2	90	Std. Mean Difference (IV, Random, 95% CI)	0.13 [-0.64, 0.90]
2 All-cause mortality	4	156	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Hypoglycaemic episodes	4	156	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.23, 1.52]
3.1 Adults	3	110	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.11, 3.94]
3.2 Children	1	46	Risk Ratio (M-H, Random, 95% CI)	0.56 [0.18, 1.72]
4 Length of hospital stay	2	90	Mean Difference (IV, Random, 95% CI)	-0.38 [-0.97, 0.22]








#### Analysis 1.1. Comparison 1 Insulin lispro versus regular insulin, Outcome 1 Time to resolution of diabetic ketoacidosis.

Study or subgroup	Insulin lispro		Regular insulin		Std. Mean Difference Random, 95% CI	Weight	Std. Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
Karoli 2011	25	12 (2.2)	25	11 (1.6)		51.46%	0.51 [-0.05, 1.08]
Umpierrez 2004a	20	10 (3)	20	11 (4)		48.54%	-0.28 [-0.9, 0.35]
<b>Total ***</b>	<b>45</b>		<b>45</b>			<b>100%</b>	<b>0.13 [-0.64, 0.9]</b>
Heterogeneity: Tau <sup>2</sup> =0.22; Chi <sup>2</sup> =3.38, df=1 (P=0.07); I <sup>2</sup> =70.45%							
Test for overall effect: Z=0.33 (P=0.74)							
Favours insulin lispro						Favours regular insulin	




### Analysis 1.2. Comparison 1 Insulin lispro versus regular insulin, Outcome 2 All-cause mortality.


Study or subgroup	Insulin lispro n/N	Regular insulin n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Umpierrez 2004a	0/20	0/20			Not estimable
Della Manna 2005	0/25	0/21			Not estimable
Ersöz 2006	0/10	0/10			Not estimable
Karoli 2011	0/25	0/25			Not estimable
<b>Total (95% CI)</b>	<b>80</b>	<b>76</b>			<b>Not estimable</b>
Total events: 0 (Insulin lispro), 0 (Regular insulin)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
					

### Analysis 1.3. Comparison 1 Insulin lispro versus regular insulin, Outcome 3 Hypoglycaemic episodes.

Study or subgroup	Insulin lispro n/N	Regular insulin n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
<b>1.3.1 Adults</b>					
Umpierrez 2004a	1/20	1/20		12.33%	1[0.07,14.9]
Ersöz 2006	0/10	0/10			Not estimable
Karoli 2011	1/25	2/25		16.49%	0.5[0.05,5.17]
<b>Subtotal (95% CI)</b>	<b>55</b>	<b>55</b>		<b>28.82%</b>	<b>0.67[0.11,3.94]</b>
Total events: 2 (Insulin lispro), 3 (Regular insulin)					
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.14, df=1(P=0.7); I <sup>2</sup> =0%					
Test for overall effect: Z=0.44(P=0.66)					
<b>1.3.2 Children</b>					
Della Manna 2005	4/25	6/21		71.18%	0.56[0.18,1.72]
<b>Subtotal (95% CI)</b>	<b>25</b>	<b>21</b>		<b>71.18%</b>	<b>0.56[0.18,1.72]</b>
Total events: 4 (Insulin lispro), 6 (Regular insulin)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.01(P=0.31)					
<b>Total (95% CI)</b>	<b>80</b>	<b>76</b>		<b>100%</b>	<b>0.59[0.23,1.52]</b>
Total events: 6 (Insulin lispro), 9 (Regular insulin)					
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.17, df=2(P=0.92); I <sup>2</sup> =0%					
Test for overall effect: Z=1.09(P=0.28)					
Test for subgroup differences: Chi <sup>2</sup> =0.03, df=1 (P=0.86), I <sup>2</sup> =0%					
					

### Analysis 1.4. Comparison 1 Insulin lispro versus regular insulin, Outcome 4 Length of hospital stay.


Study or subgroup	Insulin lispro		Regular insulin		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
Umpierrez 2004a	20	4 (2)	20	4 (1)		37.12%	0[-0.98,0.98]
Karoli 2011	25	6 (1.2)	25	6.6 (1.5)		62.88%	-0.6[-1.35,0.15]
							




## Comparison 2. Insulin aspart versus regular insulin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Time to resolution of diabetic ketoacidosis	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2 All-cause mortality	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
3 Hypoglycaemic episodes	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
4 Length of hospital stay	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected


### Analysis 2.1. Comparison 2 Insulin aspart versus regular insulin, Outcome 1 Time to resolution of diabetic ketoacidosis.



### Analysis 2.2. Comparison 2 Insulin aspart versus regular insulin, Outcome 2 All-cause mortality.




### Analysis 2.3. Comparison 2 Insulin aspart versus regular insulin, Outcome 3 Hypoglycaemic episodes.





### Analysis 2.4. Comparison 2 Insulin aspart versus regular insulin, Outcome 4 Length of hospital stay.

Study or subgroup	Insulin aspart		Regular insulin		Mean Difference	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI	Fixed, 95% CI
Umpierrez 2004b	15	3.4 (3)	15	4.5 (3)		-1.1[-3.25,1.05]
					Favours insulin aspart	Favours regular insulin

## ADDITIONAL TABLES

**Table 1. Overview of study populations**

	Intervention(s) and comparator(s)	Sample size <sup>a</sup>	Screened/eligible [N]	Ran-domised [N]	Analysed [N]	Finishing trial [N]	Ran-domised finishing trial [%]	Fol-low-up time <sup>b</sup>
<b>Umpierrez 2004a</b>	I: s.c. insulin lispro	Arbitrary estimation of a difference between groups of $\geq 5$ hours to determine ketoacidosis as being clinically important; a sample size of 20 participants was needed in each group to provide a power of 0.93, given an alpha level of 0.05, a SD of 4, and a 1:1 inclusion ratio	-	20	20	20	100	Mean hos-pi-tal stay: 4 days
	C: i.v. regular insulin			20	20	20	100	
	<b>total:</b>			40	40	40	100	
<b>Umpierrez 2004b</b>	I1: s.c. insulin aspart, every hour	Arbitrary estimation of a difference between groups of $\geq 4$ hours to determine ketoacidosis as being clinically significant. A sample size of 15 participants was needed in each group to provide a power of 0.81, given an alpha error of 0.05 and a SD of 3	-	15	15	15	100	Mean hos-pi-tal stay: 3.4 days
	I2: s.c. insulin aspart, every 2 h			15	15	15	100	Mean hos-pi-tal stay: 3.9 days
	C: i.v. regular insulin			15	15	15	100	Mean hos-pi-tal stay: 4.5 days
	<b>total:</b>			45	45	45	100	
<b>Della Man-na 2005</b>	I: s.c. insulin lispro	-	-	25	25	25	100	Mean hos-

**Table 1. Overview of study populations** (Continued)

	C: i.v. regular insulin		21	21	21	100	pi- tal stay: 2-3 days
	<b>total:</b>		46	46	46	100	
<b>Ersöz 2006</b>	I: s.c. insulin lispro	-	10	10	10	100	-
	C: i.v. regular insulin		10	10	10	100	
	<b>total:</b>		20	20	20	100	
<b>Karoli 2011</b>	I: s.c. insulin lispro	-	25	25	25	100	Mean hos- pi- tal stay: 6 days
	C: i.v. regular insulin		25	25	25	100	Mean hos- pi- tal stay: 6.6 days
	<b>total:</b>		50	50	50	100	
<b>Grand total</b>	<b>All interventions</b>		<b>110</b>		<b>110</b>		
	<b>All c omparators</b>		<b>91</b>		<b>91</b>		
	<b>All interventions and c omparators</b>		<b>201</b>		<b>201</b>		

<sup>a</sup>According to power calculation in study publication or report

<sup>b</sup>Duration of intervention and/or follow-up under randomised conditions until end of study

- denotes not reported

C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous; SD: standard deviation

## APPENDICES

### Appendix 1. Search strategies

---

#### Cochrane Library

---

1. [mh "Diabetic Ketoacidosis"]
  2. [mh "Diabetic Coma"]
  3. (("hyperglycaemic" or "hyperglycemic" or diabet\*) next emergenc\*):ti,ab,kw
  4. (diabet\* and (keto\* or acidos\* or "coma")):ti,ab,kw
  5. "DKA":ti,ab,kw
  6. {or #1-#5}
  7. [mh "Insulin Lispro"]
  8. [mh "Insulin Aspart"]
  9. [mh "Insulin, Short-Acting"]
  10. ("glulisine" or "apidra"):ti,ab,kw
  11. ("humulin" or "novolin"):ti,ab,kw
  12. ("lispro" or "aspart"):ti,ab,kw
  13. ("novolog" or "novorapid"):ti,ab,kw
  14. (insulin\* near/4 analogue\*):ti,ab,kw
  15. (acting next insulin\*):ti,ab,kw
  16. {or #7-#15}
  17. #6 and #16
- 

#### MEDLINE (Ovid SP)

---

1. Diabetic Ketoacidosis/
  2. Diabetic Coma/
  3. ((hyperglyc?emic or diabet\*) adj emergenc\*).tw.
  4. (diabet\* and (keto\* or acidos\* or coma)).tw.
  5. DKA.tw.
  6. or/1-5
  7. Insulin Lispro/
  8. Insulin Aspart/
  9. Insulin, Short-Acting/
  10. (glulisine or apidra).tw.
  11. (humulin or novolin).tw.
  12. (lispro or aspart).tw.
  13. (novolog or novorapid).tw.
  14. (insulin\* adj3 analogue\*).tw.
  15. acting insulin\*.tw.
  16. or/7-15
  17. 6 and 16
  18. exp animals/ not humans/
  19. 17 not 18
- 

#### PubMed

---

- #1 (hyperglycemic emergenc\*[tw] OR hyperglycaemic emergenc\*[tw] OR diabetic emergenc\*[tw] OR (diabet\*[tw] AND (ketoac\*[tw] OR acidos\*[tw] OR coma[tw]))) OR DKA[tw])
- #2 (glulisine[tw] OR apidra[tw] OR humulin[tw] OR novolin[tw] OR lispro[tw] OR aspart[tw] OR novolog[tw] OR novorapid[tw] OR (insulin[tw] AND analog\*[tw]) OR acting insulin\*[tw])
- #3 #1 AND #2
- #4 #3 NOT medline[sb] NOT pmcbook
-

(Continued)

**EMBASE (Ovid SP)**

1. diabetic ketoacidosis/
2. diabetic coma/
3. ((hyperglyc?emic or diabet\*) adj emergenc\*).tw.
4. (diabet\* and (keto\* or acidosis\* or coma)).tw.
5. DKA.tw.
6. or/1-5
7. insulin lispro/
8. insulin aspart/
9. insulin glulisine/
10. short acting insulin/
11. (glulisine or apidra).tw.
12. (humulin or novolin).tw.
13. (lispro or aspart).tw.
14. (novolog or novorapid).tw.
15. (insulin\* adj3 analogue\*).tw.
16. acting insulin\*.tw.
17. or/7-16
18. 6 and 17
- [19: Wong et al. 2006 "sound treatment studies" filter – BS version]
19. random\*.tw. or clinical trial\*.mp. or exp health care quality/
20. 18 and 19
21. limit 20 to embase

**LILACS (IAHx)**

(MH: "Diabetic Ketoacidosis" OR MH: "Diabetic Coma" OR (diabet\$ AND (keto\$ OR acidosis\$ OR "coma"))) AND (MH: "Insulin Lispro" OR MH: "Insulin Aspart" OR MH: "Insulin, Short-Acting" OR ("glulisine" OR "apidra") OR ("humulin" OR "novolin") OR ("lispro" OR "aspart") OR ("novolog" OR "novorapid") OR (insulin\$ AND analogue\$) OR (acting AND insulin\$))  
+ Filter "Controlled Clinical Trial"

**CINAHL (Ebsco)**

- S1. MH "Diabetic Ketoacidosis"
- S2. MH "Diabetic Coma"
- S3. TI (("hyperglycaemic" OR "hyperglycemic" OR diabet\*) N1 emergenc\*) OR AB (("hyperglycaemic" OR "hyperglycemic" OR diabet\*) N1 emergenc\*)
- S4. TI (diabet\* AND (keto\* OR acidosis\* OR "coma")) OR AB (diabet\* AND (keto\* OR acidosis\* OR "coma"))
- S5. TI ("DKA") OR AB ("DKA")
- S6. S1 OR S2 OR S3 OR S4 OR S5
- S7. MH "Insulin Lispro"
- S8. MH "Insulin Aspart"
- S9. MH "Insulin, Short-Acting"
- S10. TI ("glulisine" OR "apidra") OR AB ("glulisine" OR "apidra")
- S11. TI ("humulin" OR "novolin") OR AB ("humulin" OR "novolin")
- S12. TI ("lispro" OR "aspart") OR AB ("lispro" OR "aspart")
- S13. TI ("novolog" OR "novorapid") OR AB ("novolog" OR "novorapid")
- S14. TI (insulin\* N3 analogue\*) OR AB (insulin\* N3 analogue\*)
- S15. TI (acting N1 insulin\*) OR AB (acting N1 insulin\*)
- S16. S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15
- S17. S6 AND S16

**ICTRP Search Portal**

Standard search:

diabet\* AND keto\* AND lispro OR  
diabet\* AND acidosis\* AND lispro OR  
diabet\* AND coma AND lispro OR

(Continued)

diabet\* AND keto\* AND aspart OR  
diabet\* AND acidosis\* AND aspart OR  
diabet\* AND coma AND aspart OR  
diabet\* AND keto\* AND acting insulin OR  
diabet\* AND acidosis\* AND acting insulin OR  
diabet\* AND coma AND acting insulin OR  
diabet\* AND keto\* AND analogue\* OR  
diabet\* AND acidosis\* AND analogue\* OR  
diabet\* AND coma AND analogue\* OR  
diabet\* AND keto\* AND glulisine OR  
diabet\* AND acidosis\* AND glulisine OR  
diabet\* AND coma AND glulisine

## ClinicalTrials.gov

### Advanced Search

**Search terms:** ((diabetic OR diabetes) AND (ketoacidosis OR ketoacidoses OR acidosis OR acidoses OR ketosis OR ketoses OR coma)) AND (lispro OR aspart OR glulisine OR acting insulin OR apidra OR humulin OR novolin OR novolog OR novorapid OR analogue OR analogues)

## Appendix 2. Description of interventions

	Intervention(s)	Ade- quate <sup>a</sup> in- terven- tion  (Yes/No)	Comparator(s)	Ade- quate <sup>a</sup> compar- ator  (Yes/No)
Umpier- rez 2004a	Subcutaneous insulin lispro every hour: initial in- jection of 0.3 units/kg followed by 0.1 unit/kg/h until blood glucose levels reached 250 mg/dL; the insulin dose was then reduced to 0.05 units/kg/h, and the intravenous fluids were changed to dex- trose 5% in 0.45% normal saline to keep blood glucose at a level of about 200 mg/dL until resolu- tion of DKA	Yes	Intravenous regular insulin: initial bo- lus of 0.1 units/kg, followed by a con- tinuous infusion of 0.1 units/kg/h un- til blood glucose levels decreased to approx. 250 mg/dL; at this time, intra- venous fluids were changed to dex- trose-containing solutions, and the in- sulin infusion rate was decreased to 0.05 units/kg/h until resolution of DKA	Yes
Umpier- rez 2004b	I1: initial injection of 0.3 units/kg, followed by 0.1 units/kg/h until blood glucose reached 250 mg/dL; the insulin dose was then reduced to 0.05 units/kg/h, and the intravenous fluids were changed to dextrose 5%, 0.45 saline to maintain blood glucose at 200 mg/dL until resolution of DKA	Yes	Intravenous regular insulin: initial bo- lus of 0.1 units/kg, followed by a con- tinuous infusion of regular insulin cal- culated to deliver 0.1 units/kg/h until blood glucose levels were 250 mg/dL; the insulin dose was then reduced to 0.05 units/kg/h, and the intravenous fluids were changed to dextrose 5%, 0.45 saline to maintain blood glucose at 200 mg/dL until resolution of DKA	Yes
	I2: initial dose of 0.3 units/kg followed by 0.2 units/kg 1 h later and every 2 h until blood glu- cose reached 250 mg/dL; the insulin dose was then reduced to 0.1 units/kg every 2 h, and the in- travenous fluids were changed to dextrose 5%, 0.45 saline to keep blood glucose at 200 mg/dL until resolution of DKA	Yes		

(Continued)

<b>Della Manna 2005</b>	0.15 units/kg of a insulin lispro was administered subcutaneously every 2 h; when capillary blood glucose levels neared 249 mg/dL, 0.15 units/kg were administered every 4 h for the next 24 h  After approx. 12 h of intensive insulin administration, intermediate human insulin was initiated at a dosage of 0.4 unit/kg every 12 h	Yes	Regular insulin was infused with a syringe pump at a rate of 0.1 unit/kg/h from an independent intravenous line through a second catheter inserted into a peripheral vein. This infusion was continued until capillary blood glucose levels decreased to $\leq 249$ mg/dL; thereafter, 0.15 units/kg regular insulin were given subcutaneously 30 min before stopping the intravenous line and every 4 h for the next 24 h  After approx. 12 h of intensive insulin administration, intermediate human insulin was initiated at a dosage of 0.4 unit/kg every 12 h	Yes
<b>Ersöz 2006</b>	Following a bolus injection of 0.15 units/kg i.v. regular insulin, group L received half of this dose as hourly s.c. insulin lispro. Insulin dose was titrated according to serum glucose and pH levels; if serum glucose did not fall by 50-70 mg/dL in the first hour, insulin dose was planned to be doubled hourly until glucose fell by 50-70 mg/dL	Yes	Following a bolus injection of 0.15 units/kg i.v. regular insulin, group R was treated conventionally with standard i.v. regular insulin infusion. Insulin dose was titrated according to serum glucose and pH levels; if serum glucose did not fall by 50-70 mg/dL in the first hour, insulin dose was planned to be doubled hourly until glucose fell by 50-70 mg/dL	Yes
<b>Karoli 2011</b>	Initial bolus of 0.3 units/kg followed by 0.2 units/kg 1 h later and then 0.2 units/kg every 2 h until blood glucose reached 250 mg/dL; the insulin dose was then reduced to 0.1 units/kg/h to keep blood glucose at approx. 200 mg/dL	Yes	Initial bolus of regular insulin 0.1 unit/kg i.v. followed by continuous infusion of regular insulin calculated to deliver 0.1 unit/kg/h until blood glucose levels decreased to approx. 250 mg/dL; the insulin infusion rate was then decreased to 0.05 units/kg/h until resolution of DKA, and intravenous fluids were changed to dextrose-containing solutions (5% dextrose) to keep blood glucose level at approx. 200 mg/dL	Yes

<sup>a</sup>The term 'adequate' refers to sufficient use of the intervention/comparator with regard to dose, dose escalation, dosing scheme, provision for contraindications, and other features necessary to establish a fair contrast between intervention and comparator.

DKA: diabetic ketoacidosis; I: intervention

### Appendix 3. Baseline characteristics (I)



	Inter- ven- tion(s) and com- para- tor(s)	Duration of intervention (duration of follow-up) [days, months, years ...]	Descrip- tion of parti- pants	Trial period [year to year]	Country	Setting	Ethnic groups [%]	Duration of diabetes [mean/ range years (SD), or as reported]
<b>Umpierrez 2004a</b>	I: s.c. insulin lispro	Resolution of DKA: mean 10 h (mean hospital stay: 4 d)	Adults with "un- complicat- ed" DKA (not stat- ed if type 1 or 2 dia- betes)	-	USA	Regional medical centre  DKA established in the ED  Regular medicine ward, intermedi- ate care unit (step- down unit)	African American: 75	6.7 (5)
	C: i.v. regular insulin	Resolution of DKA: mean 11 h (mean hospital stay: 4 d)				Regional medical centre  DKA established in the ED  ICU	African American: 80	6.9 (4)
<b>Umpierrez 2004b</b>	I1: s.c. insulin aspart, every hour	Resolution of DKA: mean 10 h (mean hospital stay: 3.4 d)	Adults with "un- complicat- ed" DKA (not stat- ed if type 1 or 2 dia- betes)	-	USA	Regional medical centre  DKA established in the ED  General medical ward or step-down unit	-	-
	I2: s.c. insulin aspart, every 2 h	Resolution of DKA: mean 10.7 h (mean hospital stay: 3.9 d)						
	C: i.v. regular insulin	Resolution of DKA: mean 11 h (mean hospital stay: 4.5 d)				Regional medical centre DKA established in the ED  ICU		

(Continued)

<b>Della Man- na 2005</b>	I: s.c. insulin lispro	Resolution of metabolic acidosis/ketosis: "in the next 6 h interval" (later than after i.v. reg- ular insulin)  Resolution of DKA: 12 h after capillary glucose < 250 mg/dL  (mean hospital stay 2-3 d)	Children and ado- lescents with DKA	2001 to 2003	Brazil	University chil- dren's hospital, 57 DKA episodes treat- ed in ED, 3 DKA episodes treated in ICU	-	-
	C: i.v. regular insulin	Resolution of metabolic acidosis/ketosis: 6 h after capillary glucose ≤ 250 mg/dL  Resolution of DKA: 12 h after capillary glucose < 250 mg/dL  (mean hospital stay 2-3 d)						
<b>Ersöz 2006</b>	I: s.c. insulin lispro	Resolution of DKA: no data (hospital stay: no data)	Adults with mild or moder- ate DKA (not stat- ed if type 1 or 2 dia- betes)	-	Turkey	-	-	3.9 (4.5)
	C: i.v. regular insulin							4.5 (4.3)
<b>Karoli 2011</b>	I: s.c. insulin lispro	Resolution of DKA: mean 12 h (mean hospital stay 6 d)	Adults with mild to moder- ate DKA (> 50% of partici- pants had type 2 dia- betes)	2009 to 2010	India	Teaching hospital, ED	-	6.4 (5)
	C: i.v. regular insulin	Resolution of DKA: mean 11 h (mean hospital stay 6.6 d)				Teaching hospital, ICU		6.8 (4)

- denotes not reported

C: comparator; d: days; DKA: diabetic ketoacidosis; ED: emergency department; h: hours; I: intervention; ICU: intensive care unit; i.v.: intravenous; s.c.: subcutaneous; SD: standard deviation

---

**Appendix 4. Baseline characteristics (II)**

	Intervention(s) and comparator(s)	Sex [female %]	GluAge cos (mean lev-years (SD)) els at admission (mean mg/dL (SD))	HbA1c (mean % (SD))	BMI (mean kg/m <sup>2</sup> (SD))	Comedications / Cointerventions	Comorbidities
<b>Umpierrez 2004a</b>	I: s.c. insulin lispro	40	67437 (12) (154)	-	26 (7)	-	-
	C: i.v. regular insulin	35	61139 (14) (264)	-	27 (9)	-	-
<b>Umpierrez 2004b</b>	I1: s.c. insulin aspart, every hour	27	78736 (8) (378)	11.5 (1.6)	27 (6)	-	27% had an associated comorbid condition (leg abscess, pneumonia, urinary tract infection, pancreatitis)
	I2: s.c. insulin aspart, every 2 h	33	75838 (12) (373)	11.4 (2)	29 (7)	-	27% had an associated medical illness (cellulitis, urinary tract infection, olanzapine overdose, failure to take oral antidiabetic agent)
	C: i.v. regular insulin	33	71740 (13) (239)	11.7 (2)	27 (7)	-	27% had an associated medical illness (pneumonia, cellulitis, urinary tract infection, and tooth abscess)
<b>Della Man-na 2005</b>	I: s.c. insulin lispro	68	43411 (4) (142)	-	-	-	-
	C: i.v. regular insulin	76	43412 (3) (146)	-	-	-	-
<b>Ersöz 2006</b>	I: s.c. insulin lispro	50	51239 (20) (138)	13.9 (2.3)	-	-	Retinopathy/neuropathy/nephropathy/cardiovascular disease/cerebrovascular disease: 10%/10%/0%/10%/10%

(Continued)

	C: i.v. regular insulin	60	55649 (18) (43)	11.6 (1.7)	-	-	Retinopathy/neuropathy/nephropathy/car- diovascular disease/cerebrovascular disease: 20%/20%/0%/30%/0%
<b>Karoli 2011</b>	I: s.c. insulin lispro	44	65034 (13) (113)	-	25 (3)	-	-
	C: i.v. regular insulin	36	67935 (11) (125)	-	24 (2)	-	-

- denotes not reported

BMI: body mass index; C: comparator; HbA1c: glycosylated haemoglobin A1c; I: intervention; i.v.: intravenous; s.c.: subcutaneous; SD: standard deviation

## Appendix 5. Matrix of study endpoints (publications and trial documents)

	End-points quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper) <sup>a</sup>	Study results posted in trial register, publications specified in trial register	Endpoints quoted in publication(s) <sup>b,c</sup>	Endpoints quoted in abstract of publication(s) <sup>b,c</sup>
Umpierrez 2004a	N/T		<b>Primary outcome measure(s):</b> response to medical therapy: the time required for resolution of hyperglycaemia and ketoacidosis, and the rate of hypoglycaemia during insulin infusion	<b>Primary outcome measure(s):</b> -
			<b>Secondary outcome measure(s):</b> -	<b>Secondary outcome measure(s):</b> -
			<b>Other outcome measure(s):</b> levels of blood glucose, electrolytes, phosphorus, venous pH, beta-hydroxybutyrate, free fatty acids, insulin; medical care data (site of admission and treatment in the hospital, amount of fluid and insulin administration, length of hospitalisation); deaths	<b>Other outcome measure(s):</b> duration of treatment until correction of hyperglycaemia and resolution of ketoacidosis, deaths, length of hospital stay, amount of insulin until resolution of diabetic ketoacidosis, rate of hypoglycaemia, hospitalisation charges
Umpierrez 2004b	N/T		<b>Primary outcome measure(s):</b> time to resolve ketoacidosis	<b>Primary outcome measure(s):</b> -
			<b>Secondary outcome measure(s):</b> -	<b>Secondary outcome measure(s):</b> -
			<b>Other outcome measure(s):</b> levels of glucose, electrolytes, phosphorus, venous pH, beta-hydroxybutyrate, free fatty acids, insulin; response to medical therapy (time and amount of insulin required for resolution of hyperglycaemia and ketoacidosis and the number of hypoglycaemic events during therapy)	<b>Other outcome measure(s):</b> duration of treatment until resolution of hyperglycaemia and ketoacidosis, total length of hospitalisation, amount of insulin administration until resolution of hyperglycaemia and ketoacidosis, number of hypoglycaemic events
Della Manna 2005	N/T		<b>Primary outcome measure(s):</b> -	<b>Primary outcome measure(s):</b> -
			<b>Secondary outcome measure(s):</b> -	<b>Secondary outcome measure(s):</b> -
			<b>Other outcome measure(s):</b> blood glucose, blood gas, beta-hydroxybutyrate, electrolytes, phosphate, magnesium, urea nitrogen, creatinine, urine ketones; resolution of metabol-	<b>Other outcome measure(s):</b> blood glucose, blood gas, beta-hydroxybutyrate, electrolytes, metabolic acidosis and keto-sis, DKA recovery

(Continued)

		ic acidosis and ketosis, DKA recovery; (near) deaths, cerebral oedema; hypoglycaemic episodes	
<b>Ersöz 2006</b>	N/T	<b>Primary outcome measure(s): -</b>	<b>Primary outcome measure(s): -</b>
		<b>Secondary outcome measure(s): -</b>	<b>Secondary outcome measure(s): -</b>
		<b>Other outcome measure(s):</b> serum glucose, pH, beta-hydroxybutyrate, electrolytes, urine ketone levels and urinary output, lipids; resolution of ketoacidosis, time elapsed until normalisation of the monitored parameters, total amount of insulin delivered until resolution of DKA; mortality, hypoglycaemic events	<b>Other outcome measure(s):</b> time needed for normalisation of serum glucose, beta-hydroxybutyrate, blood pH and urine ketone levels; mortality, serious side effects
<b>Karoli 2011</b>	N/T	<b>Primary outcome measure(s): -</b>	<b>Primary outcome measure(s): -</b>
		<b>Secondary outcome measure(s): -</b>	<b>Secondary outcome measure(s): -</b>
		<b>Other outcome measure(s):</b> blood glucose levels, resolution of DKA, response to therapy was assessed by time and amount of insulin required for resolution of hyperglycaemia and ketoacidosis, number of hypoglycaemic events; duration of hospital stay; deaths	<b>Other outcome measure(s):</b> response to therapy (duration of treatment and amount of insulin administered until resolution of hyperglycaemia and ketoacidosis, total length of hospital stay, and number of hypoglycaemic events); mortality

- denotes not reported

<sup>a</sup>Trial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturers' websites, trial registers)

<sup>b</sup>Publication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents, or multiple reports of a primary study)

<sup>c</sup>Other outcome measures refer to all outcomes not specified as primary or secondary outcome measures

DKA: diabetic ketoacidosis; EMA: European Medicines Agency; FDA: US Food and Drug Administration; N/T: no trial document available

## Appendix 6. Examination of outcome reporting bias according to ORBIT classification

	<b>Outcome</b>	<b>High risk of bias (category A)<sup>a</sup></b>	<b>High risk of bias (category D)<sup>b</sup></b>	<b>High risk of bias (category E)<sup>c</sup></b>	<b>High risk of bias (category G)<sup>d</sup></b>
<b>Umpierrez 2004a</b>	N/A	N/A	N/A	N/A	N/A
<b>Umpierrez 2004b</b>	N/A	N/A	N/A	N/A	N/A
<b>Della Manna 2005</b>	Time to resolution of DKA	Yes	N/A	N/A	N/A
<b>Ersöz 2006</b>	Time to resolution of DKA	Yes	N/A	N/A	N/A
<b>Karoli 2011</b>	N/A	N/A	N/A	N/A	N/A



(Continued)

<sup>a</sup>Clear that outcome was measured and analysed; trial report states that outcome was analysed but reports only that result was not significant.

(Classification 'A', table 2, [Kirkham 2010](#))

<sup>b</sup>Clear that outcome was measured and analysed; trial report states that outcome was analysed, but no results reported.

(Classification 'D', table 2, [Kirkham 2010](#))

<sup>c</sup>Clear that outcome was measured but not necessarily analysed; judgement says likely to have been analysed but not reported because of non-significant results.

(Classification 'E', table 2, [Kirkham 2010](#))

<sup>d</sup>Unclear whether the outcome was measured; not mentioned, but clinical judgement says likely to have been measured and analysed but not reported on the basis of non-significant results.

(Classification 'G', table 2, [Kirkham 2010](#))

DKA: diabetic ketoacidosis; N/A: not applicable; ORBIT: Outcome Reporting Bias In Trials

## Appendix 7. Definition of endpoint measurement (I)

	Resolution of diabetic ketoacidosis	All-cause mortality	Morbidity	Patient satisfaction	HbA1c	Socioeconomic effects
<b>Umpierrez 2004a</b>	Serum bicarbonate level $\geq 18$ mEq/L and venous pH $> 7.30$	N/D	N/I	N/I	N/I	Hospital stay in days and cost as data on hospital charges
<b>Umpierrez 2004b</b>	Serum bicarbonate level $\geq 18$ mmol/L and venous pH $> 7.30$	N/D	N/I	N/I	N/I	Length of hospital stay in days
<b>Della Manina 2005</b>	Mentally alert and able to eat, serum bicarbonate $> 15$ mmol/L, venous pH $> 7.30$ , anion gap $< 16$ mmol/L	N/D	Cerebral oedema	N/I	N/I	N/I
<b>Ersöz 2006</b>	Serum glucose $< 200$ mg/dL, serum bicarbonate level $> 18$ mmol/L, venous pH $> 7.30$ , capillary hydroxybutyrate level $< 0.6$ mmol/L, and negative urine ketone	N/D	N/I	N/I	N/I	N/I
<b>Karoli 2011</b>	Serum bicarbonate level $> 18$ mmol/L and arterial pH $> 7.30$	N/D	Venous thrombosis, adult respiratory distress syndrome, hyperchloeraemic acidosis	N/I	N/I	N/I

HbA1c: glycosylated haemoglobin A1c; N/D: not defined; N/I: not investigated

## Appendix 8. Definition of endpoint measurement (II)

	All hypoglycaemic events	Severe hypoglycaemia	Nocturnal hypoglycaemia	Severe/serious adverse events
<b>Umpierrez 2004a</b>	≤ 60 mg/dL	N/I	N/I	N/I
<b>Umpierrez 2004b</b>	≤ 60 mg/dL	N/I	N/I	N/I
<b>Della Manna 2005</b>	< 60 mg/dL, described as "mild"	N/I	N/I	N/I
<b>Ersöz 2006</b>	N/D	N/I	N/I	N/D
<b>Karoli 2011</b>	< 60 mg/dL, described as "mild"	N/I	N/I	N/I
N/D: not defined; N/I: not investigated				

## Appendix 9. Adverse events (I)

Intervention(s) and comparator(s)		Partici- pants in- cluded in analysis [N]	Deaths [N]	Deaths [%]	Partici- pants with at least one adverse event [N]	Partici- pants with at least one adverse event [%]	Par- tici- pants with at least one se- vere/se- rious ad- verse event [N]	Par- tici- pants with at least one se- vere/se- rious ad- verse event [%]
<b>Umpierrez 2004a</b>	I: s.c. insulin lispro	20	0	0	-	-	-	-
	C: i.v. regular insulin	20	0	0	-	-	-	-
<b>Umpierrez 2004b</b>	I1: s.c. insulin aspart, every hour	15	0	0	-	-	-	-
	I2: s.c. insulin aspart, every 2 h	15	0	0	-	-	-	-
	C: i.v. regular insulin	15	0	0	-	-	-	-
<b>Della Man- na 2005</b>	I: s.c. insulin lispro	25	0	0	-	-	-	-
	C: i.v. regular insulin	21	0	0	-	-	-	-
<b>Ersöz 2006</b>	I: s.c. insulin lispro	10	0	0	-	-	0	0
	C: i.v. regular insulin	10	0	0	-	-	0	0
<b>Karoli 2011</b>	I: s.c. insulin lispro	25	0	0	-	-	-	-
	C: i.v. regular insulin	25	0	0	-	-	-	-
- denotes not reported								
C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous								

## Appendix 10. Adverse events (II)

Intervention(s) and comparator(s)		Partici- pants in- cluded in analysis [N]	Participants discontin- ing trial due to an adverse event [N]	Participants discontin- ing trial due to an adverse event [%]
<b>Umpierrez 2004a</b>	I: s.c. insulin lispro	20	0	0
	C: i.v. regular insulin	20	0	0
<b>Umpierrez 2004b</b>	I1: s.c. insulin aspart, every hour	15	0	0
	I2: s.c. insulin aspart, every 2 h	15	0	0
	C: i.v. regular insulin	15	0	0
<b>Della Manna 2005</b>	I: s.c. insulin lispro	25	0	0
	C: i.v. regular insulin	21	-	-
<b>Ersöz 2006</b>	I: s.c. insulin lispro	10	0	0
	C: i.v. regular insulin	10	0	0
<b>Karoli 2011</b>	I: s.c. insulin lispro	25	0	0
	C: i.v. regular insulin	25	0	0

- denotes not reported

C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous

## Appendix 11. Adverse events (III)

Intervention(s) and comparator(s)		Partici- pants in- cluded in analysis [N]	Partici- pants with hypogly- caemic episodes [N]	Partici- pants with hypogly- caemic episodes [%]	Partici- pants with noctur- nal hypo- glycaemic episodes [N]	Partici- pants with noctur- nal hypo- glycaemic episodes [% partici- pants]	Partici- pants with severe/se- rious hypo- glycaemic episodes [N]	Partici- pants with severe/se- rious hypo- glycaemic episodes [%]
<b>Umpierrez 2004a</b>	I: s.c. insulin lispro	20	1	5	-	-	-	-
	C: i.v. regular insulin	20	1	5	-	-	-	-
<b>Umpierrez 2004b</b>	I1: s.c. insulin aspart, every hour	15	1	6.6	-	-	-	-
	I2: s.c. insulin aspart, every 2 h	15	1	6.6	-	-	-	-
	C: i.v. regular insulin	15	1	6.6	-	-	-	-
<b>Della Man- na 2005</b>	I: s.c. insulin lispro	25	4	16	-	-	-	-
	C: i.v. regular insulin	21	6	29	-	-	-	-
<b>Ersöz 2006</b>	I: s.c. insulin lispro	10	0	0	-	-	-	-
	C: i.v. regular insulin	10	0	0	-	-	-	-
<b>Karoli 2011</b>	I: s.c. insulin lispro	25	1	4	-	-	-	-
	C: i.v. regular insulin	25	2	8	-	-	-	-
- denotes not reported								
C: comparator; I: intervention; i.v.: intravenous; s.c.: subcutaneous								

---

**Appendix 12. Checklist to aid consistency and reproducibility of GRADE assessments**

'Summary of findings' tables outcome measures (for both insulin lispro and insulin aspart)		All-cause mortality	Hypoglycaemic episodes	Morbidity	Adverse events other than hypoglycaemic episodes	Time to resolution of diabetic ketoacidosis	Patient satisfaction	Socioeconomic effects (length of hospital stay)
<b>Trial limitations (risk of bias)<sup>a</sup></b>	Was random sequence generation used (i.e. no potential for selection bias)?	Unclear	Yes/unclear	N/A	N/I	Unclear	N/I	Yes/unclear
	Was allocation concealment used (i.e. no potential for selection bias)?	Unclear	Unclear			Unclear		Unclear
	Was there blinding of participants and personnel (i.e. no potential for performance bias)?	No	No (↓)			No (↓)		No (↓)
	Was there blinding of outcome assessment (i.e. no potential for detection bias)?	Unclear	Unclear			Unclear		No (↓)
	Was an objective outcome used?	Yes	Yes			Yes		Yes
	Were more than 80% of participants enrolled in trials included in the analysis (i.e. no potential reporting bias)? <sup>e</sup>	Yes	Yes			Yes		Yes
	Were data reported consistently for the outcome of interest (i.e. no potential selective reporting)?	Yes	Yes			Unclear		Yes
	No other biases reported (i.e. no potential for other bias)?	Yes	Yes			Yes		Yes
	Did the trials end as scheduled (i.e. not stopped early)?	Yes	No			Yes		Yes
<b>Inconsistency<sup>b</sup></b>	Point estimates did not vary widely?	N/A	Yes <sup>f</sup>			Yes <sup>f</sup>		Yes <sup>f</sup>
	To what extent did confidence intervals overlap (substantial: all confidence intervals overlap at least 1 of the included studies' point estimate; some: confidence intervals overlap, but not all overlap at least 1 point estimate; no: at	N/A	Substantial <sup>f</sup>			Substantial <sup>f</sup>		Substantial <sup>f</sup>



(Continued)

least 1 outlier: where the confidence interval of some of the studies does not overlap with those of most included studies)?

	Was the direction of effect consistent?	Yes	Yes <sup>f</sup>
	What was the magnitude of statistical heterogeneity (as measured by I <sup>2</sup> ): low (I <sup>2</sup> < 40%), moderate (I <sup>2</sup> 40% - 60%), high (I <sup>2</sup> > 60%)?	N/A	Low <sup>f</sup>
	Was the test for heterogeneity statistically significant (P < 0.1)?	N/A	Not statistically significant <sup>f</sup>
<b>Indirectness<sup>a</sup></b>	Were the populations in the included studies applicable to the decision context?	Highly applicable	Highly applicable
	Were the interventions in the included studies applicable to the decision context?	Highly applicable	Highly applicable
	Was the included outcome not a surrogate outcome?	Yes	Yes
	Was the outcome time frame sufficient?	Sufficient	Sufficient
	Were the conclusions based on direct comparisons?	Yes	Yes
<b>Imprecision<sup>c</sup></b>	Was the confidence interval for the pooled estimate not consistent with benefit and harm?	N/A	No (↓) <sup>f</sup>
	What is the magnitude of the median sample size (high: 300 participants, intermediate: 100-300 participants, low: < 100 participants)? <sup>e</sup>	Intermediate <sup>g</sup>	Intermediate <sup>g</sup>
	What was the magnitude of the number of included studies (large: > 10 studies, moderate: 5-10 studies, small: < 5 studies)? <sup>e</sup>	Small (↓)	Small (↓)
	Was the outcome a common event (e.g. occurs more than 1/100)?	N/A	Yes

No (↓) <sup>f</sup>	Yes <sup>f</sup>
High (↓) <sup>f</sup>	Low <sup>f</sup>
Not statistically significant <sup>f</sup>	Not statistically significant <sup>f</sup>
Highly applicable	Highly applicable
Highly applicable	Highly applicable
Yes	Yes
Sufficient	Sufficient
Yes	Yes
No (↓) <sup>f</sup>	No (↓) <sup>f</sup>
Low (↓)	Low (↓)
Small (↓)	Small (↓)
N/A	N/A

(Continued)

<b>Publication bias<sup>d</sup></b>	Was a comprehensive search conducted?	Yes	Yes	Yes	Yes
	Was grey literature searched?	No (↓)	No (↓)	No (↓)	No (↓)
	Were no restrictions applied to study selection on the basis of language?	Yes	Yes	Yes	Yes
	There was no industry influence on studies included in the review?	No (↓)	No (↓)	No (↓)	No (↓)
	There was no evidence of funnel plot asymmetry?	N/A	Unclear	Unclear	Unclear
	There was no discrepancy in findings between published and unpublished trials?	Unclear	Unclear	Unclear	Unclear

<sup>a</sup>Questions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials

<sup>b</sup>Questions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on  $I^2$

<sup>c</sup>When judging the width of the confidence interval, it is recommended to use a clinical decision threshold to assess whether the imprecision is clinically meaningful

<sup>d</sup>Questions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published and unpublished trials

<sup>e</sup>Depends on the context of the systematic review area

<sup>f</sup>N/A for insulin aspart

<sup>g</sup>Low for insulin aspart

(↓): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of findings' table(s)

GRADE: Grading of Recommendations Assessment, Development and Evaluation; N/A: not applicable; N/I: not investigated

## Appendix 13. Survey of authors providing information on included trials

	Date trial author contacted	Date trial author replied	Trial author asked for additional information [short summary]	Trial author provided data [short summary]
<b>Umpierrez 2004a</b>	2 April 2015	No reply	N/A	N/A
<b>Umpierrez 2004b</b>	2 April 2015	No reply	N/A	N/A
<b>Della Manna 2005</b>	2 April 2015	No reply	N/A	N/A
<b>Ersöz 2006</b>	2 April 2015	No reply	N/A	N/A
<b>Karoli 2011</b>	2 April 2015	No reply	N/A	N/A
<b>El Ebrashy 2010</b>	2 April 2015	No reply	N/A	N/A
<b>Baldwin 2009</b>	2 April 2015	No reply	N/A	N/A
N/A: not applicable				

## CONTRIBUTIONS OF AUTHORS

Carlos A Andrade-Castellanos (CAC): protocol drafting, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation.

Luis E Colunga-Lozano (LCL): acquiring trial reports, trial selection, data extraction, data analysis, data interpretation, review drafting, and future review updates.

Netzahualpilli Delgado-Figueroa (NDF): protocol drafting, acquiring trial reports, data analysis, data interpretation, review drafting, and future review updates.

Daniel A Gonzalez-Padilla (DGP): acquiring trial reports, data analysis, review drafting, and future review updates.

## DECLARATIONS OF INTEREST

CAC: none known.

LCL: none known.

NDF: none known.

DGP: none known.

## SOURCES OF SUPPORT

### Internal sources

- Department of Emergency Medicine, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Mexico.

Moral support

### External sources

- No sources of support supplied

---

## NOTES

We have based parts of the background, the methods section, appendices, additional tables and figures 1 to 3 of this review on a standard template established by the CMED Group.

## INDEX TERMS

### Medical Subject Headings (MeSH)

Diabetic Ketoacidosis [\*drug therapy]; Hypoglycemic Agents [adverse effects] [\*therapeutic use]; Injections, Subcutaneous; Insulin [therapeutic use]; Insulin Aspart [therapeutic use]; Insulin Lispro [therapeutic use]; Insulin, Short-Acting [adverse effects] [\*therapeutic use]; Randomized Controlled Trials as Topic

### MeSH check words

Adult; Child; Humans; Young Adult